UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549





Form
10-K





x
            ANNUAL
      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934





For
the fiscal year ended October 31, 2008





OR





o
            TRANSITION
      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934





For the
transition period from_____________ to _____________.





Commission
file number O-24512





RENHUANG
PHARMACEUTICALS, INC.


(Exact
name of registrant as specified in its charter)





Nevada
              (State
      or other jurisdiction of
              incorporation
      or organization)
            88-1273503
              (I.R.S.
      Employer
              Identification
      No.)No.
      218, Taiping, Taiping District
              Harbin,
      Heilongjiang Province,
              P.R.
      China
              (Address
      of principal executive offices)
            150050
              (Zip
      Code)





Registrant’s
telephone number, including area code +86-451-5762-0378





Securities
registered pursuant to Section 12(b) of the Act: None





Securities
registered pursuant to Section 12(g) of the Act:





Common
Stock, par value $0.001


(Title of
class)





Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities Act. Yes oNo x





Indicate
by check mark if the registrant is not required to file reports pursuant to
Section 13 or 15(d) of the Act. Yes xNo o





Indicate
by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes oNo x





Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T ( 229.405 of this
chapter) during the preceeding 12 months (or for such shorter period that the
registrant was required to submit and post such files). Yes oNo o





Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the best
of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. o





Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of “accelerated
filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check
one):





Large accelerated
      filer
            
            Accelerated
      filerNon-accelerated
      filer
            
            Smaller
      reporting company x(Do
      not check if a smaller reporting company)





Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Act). Yes o No x





Aggregate
market value of the voting stock held by non-affiliates: $14,228,511 as based on
sales price of 0.825 per share of such stock on April 30, 2008. The voting stock
held by non-affiliates on that date consisted of 17,246,680 shares of common
stock.





As of
August,24, 2009, there were 37,239,536 shares of common stock, par value
$0.001, issued and outstanding.









Renhuang Pharmaceuticals,
Inc.





TABLE OF
CONTENTS





PART
      IITEM
      1 – BUSINESS
                
                3ITEM
      1A – RISK FACTORS
                
                18ITEM
      1B – UNRESOLVED STAFF COMMENTS
                
                26ITEM
      2 - PROPERTIES
                
                26ITEM
      3 - LEGAL PROCEEDINGS
                
                27ITEM
      4 – SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
                
                27PART
      IIITEM
      5 – MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
      ISSUER PURCHASES OF EQUITY SECURITIES
                
                27ITEM
      6 – SELECTED FINANCIAL DATA
                
                28ITEM
      7 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
      RESULTS OF OPERATION
                
                28ITEM
      7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
      RISK
                
                33ITEM
      8 – FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
                
                33ITEM
      9 – CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
      FINANCIAL DISCLOSURE
                
                34ITEM
      9A(T) – CONTROLS AND PROCEDURES
                
                34ITEM
      9B – OTHER INFORMATION
                
                35PART
      IIIITEM
      10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNACE
                
                35ITEM
      11 – EXECUTIVE COMPENSATION
                
                37ITEM
      12 – SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
      RELATED STOCKHOLDER MATTERS
                
                40ITEM
      13 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
      INDEPENDENCE
                
                41ITEM
      14 – PRINCIPAL ACCOUNTING FEES AND SERVICES
                
                41PART
      IVITEM
      15 - EXHIBITS, FINANCIAL STATEMENT SCHEDULES
                
                42




2




PART
I





Explanatory
Note





This
Annual Report includes forward-looking statements within the meaning of the
Securities Exchange Act of 1934 (the “Exchange Act”). These statements are based
on management’s beliefs and assumptions, and on information currently available
to management. Forward-looking statements include the information concerning
possible or assumed future results of operations of the Company set forth under
the heading “Management's Discussion and Analysis of Financial Condition or Plan
of Operation.” Forward-looking statements also include statements in which words
such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“consider” or similar expressions are used.





Forward-looking
statements are not guarantees of future performance. They involve risks,
uncertainties and assumptions. The Company's future results and shareholder
values may differ materially from those expressed in these forward-looking
statements. Readers are cautioned not to put undue reliance on any
forward-looking statements.





ITEM
1 – BUSINESS





Business
Overview





History
of Renhuang Pharmaceuticals, Inc.





We were
incorporated in the State of Nevada on August 18, 1988 as Solutions,
Incorporated. Since that time, we have undergone a series of name changes as
follows: Suarro Communications, Inc., e-Net Corporation, e-Net Financial Corp.,
e-Net.Com Corporation, e-Net Financial.Com Corporation, Anza Capital, Inc.
(“Anza”) and finally on July 28, 2006, we changed our name to Renhuang
Pharmaceuticals, Inc.





On March
3, 2006, we completed the disposition of substantially all of our assets and
discontinued our operations, including but not limited to, all of our ownership
interest in our subsidiary, American Residential Funding, Inc., a Nevada
corporation (“AMRES”) to AMRES Holding, LLC, a Nevada limited liability company
(“AMRES Holding”) under control of Vince Rinehart, a shareholder and, at that
time, our sole officer and director (“Rinehart”). Effective September 30, 2005,
the disposition was approved by written consent of a majority of our
stockholders.





In
exchange for substantially all of our assets, including but not limited to, all
of our ownership interest in AMRES, (i) Rinehart delivered a majority of his
ownership interest in Anza, consisting of 831,375 shares of common stock and
1,880,000 shares of our common stock acquired upon the conversion of 18,800
shares of Series F Convertible Preferred Stock, to Viking Investments USA, Inc.,
a Delaware corporation (“Viking”). Rinehart kept 156,900 shares of our common
stock; (ii) Rinehart terminated an Employment Agreement dated June 1, 2001, by
and between Rinehart and Anza; (iii) AMRES assumed all obligations under a real
property lease by and between Anza and Fifth Street Properties-DS, LLC; (iv)
AMRES delivered to Viking its ownership interest in Anza, consisting of
4,137,500 shares of our common stock; and (v) AMRES Holding delivered warrants
to acquire 250,000 shares of our common stock to Viking.





On August
11, 2006, our outstanding common stock underwent a thirty-for-one stock split
reversal resulting in a decrease in our outstanding common stock at that time
from 13,355,181 shares to approximately 445,240 shares as further described in
our Current Report filed with the Commission on April 25, 2006.  All
share amounts herein have been adjusted to reflect this reverse
split.





3




History
of Harbin Renhuang Pharmaceutical Co. Ltd. and Harbin Renhuang Pharmaceutical
Stock Co. Ltd.





Harbin
Renhuang Pharmaceutical Stock Co. Ltd. (“Old Renhuang”) was incorporated in 1996
in the Peoples Republic of China (“PRC”). Harbin Renhuang Pharmaceutical Co.
Ltd. (“Renhuang China”) was incorporated in February 2006 in the PR C. On
March 3, 2006 Renhuang Medicine for Animals, a company controlled by Mr. Li
Shaoming, invested 25 million Renminbi (or “RMB” then equal to approximately US
$3.3 million) in cash in Renhuang China. On May 1, 2006 Old Renhuang transferred
the majority of its operating assets, except buildings, to Renhuang China at the
carrying amounts of Old Renhuang.





As a
result, as of May 1, 2006, nearly 100% of revenue producing operations in Old
Renhuang were transferred to Renhuang China.





Merger
of Renhuang Pharmaceuticals and Harbin Renhuang





On August
28, 2006, Renhuang Pharmaceuticals, Inc., a Nevada corporation (the “Company”)
and a corporation incorporated under the laws of the British Virgin Island named
Harbin Renhuang Pharmaceutical Company Limited (the “BVI”) entered into a Share
Exchange Agreement (the “Agreement”) pursuant to which the Company acquired all
of the outstanding capital stock of BVI in exchange for issuing 29,750,000
shares of the Company’s common stock, par value $0.001 per share (the ‘‘Common
Stock’’) to BVI’s stockholders, representing 85% of the Company’s capital stock
on a fully diluted basis after taking into account the contemplated transaction.
BVI is a holding company and at the time owned 100% of Renhuang China. This
transaction is referred to throughout this report as the “Merger.”





Post-Merger
Business





As a
result of the Merger, all of our operations are conducted through Renhuang China
which is a wholly-owned subsidiary of the BVI which is  in turn a
wholly-owned subsidiary of the Company. Unless otherwise noted in this Annual
Report on Form 10-K all references to “we,” “us,” “our company,” “our,” or the
“Company” refer to the consolidated entity of Renhuang Pharmaceuticals, Inc.,
and its subsidiaries.





Renhuang
China was incorporated in 2006 and is located in the capital of the province of
Heilongjiang Province, in the northeastern corner of China. We are primarily
engaged in the fields of research, manufacturing and distribution of Chinese
medical products and bio-pharmaceutical products in the PRC. Our niche market is
production and sale of traditional Chinese medical products and
bio-pharmaceutical products, and our goal is to become the dominant manufacturer
and supplier of a few carefully selected groups of products, primarily natural
health care products, such as Acanthopanax and Ban Lan Gen derived from the
roots of the Isatis plant, enzyme engineering series products, including
Lysozyme enzyme, Shark Power health care products, Monoclonal Antibody Reagent
Box Series Products, and traditional medical products, such as cold, flu and
headache medicines.




Renhuang
China has the ability to produce more than 100 types of products. Our product
sales have reached more than 20 provinces and cities in China.




4




In the
beginning of 2003, Old Renhuang purchased the land use rights to 100,000 square
meters (approximately 1 million square feet) of land and built “City Bio-tech
Medicine Park” located in the City of “A” in the Province of Heilongjiang. The
project has been supported by the Chinese government in the form of a zero
percent interest rate three-year loan in the amount of RMB 30 million
(approximately US $3.7 million). The project was finished in 2004, and “City
Bio-tech Medicine Park” received a “Good Manufacturing Practice” (GMP)
certification from the Heilongjiang Food and Drug Administration on December 30,
2004. In the facility, we produce enzyme engineering series products, including
SOD (Super Oxide Dismutase), Lysozyme enzyme, Shark Power health care products
and other traditional medicine. Since May 1, 2006, Old Renhuang is leasing the
buildings to Renhuang China on market terms disclosed in this
report.





The Dongfanghong
Acquisition:





In 2003,
Old Renhuang acquired Dongfanghong Pharmaceutical Co. (DFH), a previously
state-owned pharmaceutical company located in Heilongjiang Province, which then
owned substantial amount of the wild Acanthopanax resources in Heilongjiang
Province. DFH also owned a plant used to manufacture products utilizing
Acanthopanax in the same city.  The acquisition came with 73 GMP
approved medicine products which were sold by DFH In 2004, one year after the
acquisition, Old Renhuang generated US $3.75 million in revenue from the sale of
Acanthopanax-based products and gained a 10% market share in China. As of May 1,
2006, Old Renhuang transferred all acquired operations of DFH to Renhuang
China.





In the
year ended October 31, 2008, the plant generated US $36 million in revenue of
which US $23 million in revenue was from Acanthopanax-based
products.





Products





Historically,
our medical products portfolio is divided into three different
categories:





1.  Acanthopanax
medical products - 53%*





2.  Shark
Power Healthcare products, and - 17%*





3.  Traditional
medical products. - 30%*





*
Approximate percentage of the total revenue for the fiscal year ended October
31, 2008.





Acanthopanax (Siberian
Ginseng)





Overview





Acanthopanax,
which is known in the United States as Siberian Ginseng, has been used for
centuries in China and Russia. Although a distant relative of American and Asian
ginsengs (Panaxsp.), with some overlap in its
uses, Acanthopanax is a distinct plant with different active chemical
components. Known to restore vigor, increase longevity, enhance overall health,
and stimulate both a healthy appetite and a good memory, it is used in Russia to
help the body adapt to stressful conditions and to enhance
productivity.




5




In
Chinese medicine, it is valued for its beneficial effects on “qi” (the Chinese term for vital energy
or life force, pronounced “chee.”) and its ability to treat “yang” (known in Chinese medicine as one of
the two fundamental forces, yang represents the male or active force.),
deficiency in the spleen (distinct from the Western medical
concept of spleen, this concept from traditional Chinese medicine is a way of
describing a set of interrelated parts rather than an anatomical organ.)
and the kidney. Like the panax ginsengs, Acanthopanax is considered to be an
adaptogen, which means it helps in stressful circumstances and returns the body
to a normal balanced state. For example, an adaptogen might lower blood pressure
in someone who has high blood pressure, but raise it in another person who has
low blood pressure. The active ingredients in Acanthopanax, eleutherosides
(similar to ginsenosides in the panax species), are thought to increase stamina
and to stimulate the immune system.





Until
recently, most scientific research on Acanthopanax took place in Russia and the
former Soviet Union. This research has largely supported its use to maintain
health and strengthen the body rather than to treat particular disorders.
Acanthopanax may help the body deal with physically and mentally stressful
exposures such as heat, cold, physical exhaustion, viruses, bacteria, chemicals,
extreme working conditions, noise, and pollution. By strengthening the immune
system, it may also help prevent illness. Acanthopanax is especially popular
among athletes or physical workers who require substantial sources of adaptive
energy and endurance, such as long distance runners, rock climbers, bicyclists,
scuba divers, dancers, tennis players and others seeking to enhance physical and
mental performance and endurance.




Research




Siberian
ginseng's active ingredients are a complex group of chemicals called eleutherosides.
Eleutherosides are different than the ginsenocides found in the Panax varieties of ginseng,
which is consistent with Chinese herbalists' claims that Siberian ginseng acts
differently in the body than Korean or American ginseng. There has been some
debate among herbalists whether Siberian ginseng should be considered a true
ginseng at all, due to this difference in active ingredients.




Much of
the research done on Siberian ginseng was performed by scientists in the former
Soviet Union. Many of the study results are still unavailable in English. Those
that have been translated, and more recent studies, have corroborated the
benefits of Siberian ginseng.




Siberian ginseng has been
      documented in studies to improve physical endurance, oxygen uptake,
      recovery, and overall performance in athletes, ranging from runners to
      weightlifters. A 1986 study in Japan showed that Siberian ginseng improves
      oxygen uptake in exercising
muscle.


Siberian ginseng has been
      documented to normalize blood pressure in patients with high and low blood
      pressure. Siberian ginseng has been shown to reduce stress symptoms in
      general. A 1996 study in Japan concluded that Siberian ginseng can protect
      against gastric ulcers.


Animal studies showed Siberian
      ginseng helped fight against toxic chemicals and exposure to harmful
      levels of radiation. A 1992 Russian study showed that Siberian ginseng
      reduced the occurrence of tumors in rats when exposed to radiation.
      Another Russian study showed that women undergoing radiation for breast
      cancer had a significant reduction of side effects when given
      Siberian ginseng.


A 1987 German study, using human
      subjects in a double-blind test, demonstrated that eleuthero ginseng
      boosts immune system response and enhances the body's overall resistance
      to infection. Other studies have shown that Siberian ginseng increases
      activity of lymphocytes and killer cells in the immune
      system.




Another
popular but unproven use of Acanthopanax is to maintain or restore mental
alertness.





6




Physical
Performance





Although
Acanthopanax is frequently used to enhance physical stamina and increase muscle
strength, studies have shown mixed results for these purposes.





Male
Fertility





Acanthopanax
has a long history of folkloric use for male infertility. Animal studies suggest
that Acanthopanax may be helpful in increasing reproductive
capacity.





Viral
Infection





In a
laboratory study, an extract of Acanthopanax slowed the replication of certain
viruses, including influenza A (which causes the flu) as well as human
rhinovirus and respiratory syncytial virus (both of which cause symptoms of the
common cold). A different 6-month study of 93 people with herpes simplex virus
type 2 (which generally causes genital herpes lesions) found that Acanthopanax
reduced frequency, severity, and duration of outbreaks.  It had no
effect, however, in test tubes on adenovirus (another cause of the common cold
and other respiratory infections) or herpes simplex virus type 1 (which
generally causes oral herpes lesions).





Market
Analysis on Acanthopanax in China:





The
resources for Acanthopanax medicine are mostly derived from wild Acanthopanax.
Due to favorable conditions and temperature in the Heilongjiang Province, where
Renhuang is located; 90% of the wild Acanthopanax in the PRC suitable for
medicine comes from Heilongjiang Province.





The
purchase price of Acanthopanax has been stable at RMB 2.8 per kilogram in 2007
and RMB 2.00 per kilogram in 2008.





Due to
its increasing popularity in United States, Japan and European countries,
exporting Acanthopanax medicine is expected to generate additional revenue for
us in the near future.





Future
Strategies for our Acanthopanax Products





With our
position in the marketplace, we plan to capitalize on increased brand
recognition. Through a controlled expansion plan, we plan to expand our market
shares in local provinces and eventually throughout China. We hope to eventually
be identified as the leading manufacturer of Acanthopanax products.





Through
increased market awareness, we anticipate entering into strategic foreign
partnerships, which we expect will result in increased international sale of
Acanthopanax medicine in the near future.




7




Acanthopanax
Revenue:





During
the year ended October 31, 2008, Acanthopanax medical products have generated
approximately 53% of our total revenue. Due to the amount of wild Acanthopanax
resources we control, and our technology, we believe that we will control more
than 50% share of the market of Acanthopanax-based medical products in China in
the near future. It is further anticipated that the market for
Acanthopanax-based products will continue to grow at an average annual rate of
up to 30% and thereby remain our primary revenue generating
product.





Shark Power Healthcare
Products





Shark
Power Healthcare products are made from Squalene, the scientific name for “Nose
Oil,” a low density compound stored in the liver of sharks. These medicines
contain extracts of shark liver oil and are used to improve oxygen levels in
human blood. Squalene, when taken into the body, is believed to remove animal
fat and various waste materials whilst circulating in the blood, cleaning blood
vessels and the blood stream. Traditional medicine believes that benefits
include the treatment and prevention of arteriosclerosis, improving the function
of the kidneys and liver.





Our
research and development center has developed natural medicines utilizing
Squalene - the Shark Power Healthcare Series. Our medicine was awarded the
“Special Golden Prize at the Ninth Chinese Patent Technology New Product
Exhibition,” and a gold medal at the London International Patent Technology
Exhibition.





Clinical
research has shown that this medicine can improve the ability to carry and
transport oxygen in blood, enhance the oxygen absorption and utilization factor
of an organism’s organs, dredge the blood vessels, and increase the speed of
blood's oxygen transportation and the supply of oxygen to the heart, brain, lung
and liver. It is also believed to be able to effectively treat a multitude of
symptoms caused by secondary health problems such as dizziness, insomnia, memory
loss, low energy, back pain, fatigue, and the common cold, with stable and safe
effects.





Shark
Power Healthcare Products Revenue





In the
year ended October 31, 2008, the revenue from Shark Power Healthcare products
has accounted for approximately 17% of our total revenue, compared to 13% for
the same period ended October 31, 2007.





Traditional Medical
Products





In
addition to Acanthopanax medical products and Shark Power Healthcare products,
we produce traditional medicine products, such as medicine for flu, headache,
female menstrual irregularities and other ailments. Revenue from these
traditional medical products accounted for 30% of our total revenue for the
fiscal year ended October 31, 2008, 34% of our total revenue for the fiscal
year ended October 31 2007, and 35% of our total revenue for the period from May
1, 2006 to October 31, 2006. We own 40 medical products with GMP certificates,
of which certain popular products are market leaders in their class and most
other products generate a stable stream of revenue.  We designate those
products that we believe are among our most promising products as “Star”
products.




8




Three
“Star” products





“Tianma
pills” and “Compound Yang Jiao Tablets”(also known as
“Tornado pills”) are our “Star”
traditional medicines for treating headaches. Although western headache
medicines have a larger market shares in China, they have also been shown to
have greater side effects. Research indicates that most other Chinese
traditional medicines have fewer side effects, but cannot reach the same
curative effects as western medicines.  We believe that “Tianma” and
“Tornado” not only produce strong visible curative effects, but also causes
little or no side effects.





In the
fiscal year ended October 31, 2008, revenue from the sales of “Tianma pills” and
“Compound Yang Jiao Tablets” was $3.9 million and $5 million, respectively. The
revenue from sales of the two medicines in the fiscal year ended October 31,
2007 was approximately $1.97 million and $5.42 million,
respectively.





Another
“Star” medicine of ours is “Powder For Restoring Pulse Beat” granulate (also
known as “Shengmai Granulate”). In the fiscal year ended October 31, 2008,
revenue from the sales of Shengmai Granulate was $2.5 million. In the year ended
from November 1, 2006 to October 31, 2007, revenue from this product reached
$1.9 million.





We also
produce several additional traditional medical products that each account for
lesser percentages of our total revenue. These products, through brand
recognition, generate stable revenue for us. When we expand our product
offerings, we anticipate that these additional products will be replaced by
higher margin products.





Products
in the Development Stage




We are
currently developing the following products. We began the early stages of our
research and development on these products in 2006 and, previously, these
products were developed by Old Renhuang. In the fiscal year ended October 31,
2008, we spent approximately $2.1 million on R&D.




Lysozyme
Enzyme Products




Studies
have indicated that lysozyme, an enzyme occurring naturally in egg white, human
tears, saliva, and other bodily fluids, is capable of destroying the cell walls
of certain bacteria and thereby acting as a mild antiseptic.





Egg white
has a high content of lysozyme, making egg white (albumen) the preferred raw
material for industrial production of the lysozyme enzyme.





Currently,
we do not believe there are any companies in China with the ability to produce
lysozyme on a large scale, despite the fact that it has a large potential
market. Lysozyme can be used as an antiseptic for food products, which could
compete with chemical antiseptics at a cost lower than similar products produced
outside of China.  The major uses of Lysozyme products are as
follows:





1)
Lysozyme compound biological antiseptic (food packing coating and food
bag)





2)
Lysozyme drug preparation (tablets and oral liquid)




9




3)
Lysozyme biotech pesticide





4)
Lysozyme home-use disinfectant products (paper towels, detergent, and other such
home-use cleaning products)





5)
Lysozyme biotech veterinary medicine





6)
Lysozyme biotech preparation





During
the fiscal year ended October 31, 2008, our lysozyme enzyme product is in the
preliminary testing stage. In the future, we hope to launch lysozyme enzyme
products in the food antiseptic area, which we believe is the largest potential
market for lysozyme. Our management estimates that we will achieve significant
revenue growth in this product in the next 5 years.





Monoclonal
Antibody Reagent Box Series Products





Monoclonal
Antibody Reagent Box is an excellent reagent for Immunofluorescence mapping
studies in patients with Epidermolysis Bullosa. The total sales volume of
China’s biotechnology products was approximately RMB 50 billion (US $7.2
billion) in 2008. Of this total, the sales volume of medicine and health-care
products including medicine of gene products, vaccines, diagnosis reagents,
certain antibiotics, amino acids for medical use, vitamins, blood products,
bio-chemical medicines and certain functional food was RMB 30 billion (US $4.3
billion), accounting for approximately 50 percent of the total sales volume of
the industry.





Chinese
companies in the Monoclonal Antibody Reagent Box industry are primarily small to
mid-sized privately-owned enterprises without any government support. The
production scale in China is still relatively small and it is a niche market
when compared with other developed countries. Due to the large population and
potential market in China, this area is already being pursued by certain
pharmaceutical companies.





Sales
and Marketing




We
primarily market our products through four business channels: the
over-the-counter market for non-prescription medicine, direct sales, wholesale,
and raw materials. We have more than 70 sales centers organized in 24 districts
through distributors. Furthermore, we have developed alliances with third-party
distributors who have sales channel relationships but lack manufacturing or
product development capabilities.





Four-Pronged
Approach to Achieve Market Goals





First,
our goal is to build the brand names for our products. Approximately 90% of the
Chinese population lives in the countryside and have relatively lower incomes.
Due to a diverse product mix, adjusted to appeal to lower income consumers, we
believe our traditional drugs will have a relatively high level of penetration
in those non-urban areas. Distribution to end-consumers is obtained through our
own sales personnel without middlemen costs.




10




Second,
we use key cities such as Beijing and Shanghai as our geographical sales centers
to distribute our products to major drug chain stores in urban and suburban
areas nationwide. Our approach is to use selected cities as sample targets,
supported by initial promotion and investments enabling the products to enter
into well-known drug chain stores.





Third, we
focus on top-level hospitals in the country, which have higher quality standards
and more stringent approval procedures for new products and brands.
Traditionally, hospitals in China are divided into different levels based upon
their geographic scope.  Junior level hospitals only care for smaller
geographic areas, mid-level hospitals will care for larger geographic areas, and
senior level hospitals will handle even larger regions. By focusing on the top
tier of the hospital industry, our strategy is to work from the top down and
gain access to mid- and low-level hospitals when our brands and products have
been established in the higher ranks.





Fourth,
we promote our products in the domestic media, including television, radio,
newspapers, magazines and trade publications.





Our sales
force consists of independent sales distributors that purchase our product
directly from us to sell to their customers. These independent sales
distributors may receive a rebate for a percentage of the purchase price they
pay us on certain products based on volume of product sold. Our products reach
drug stores, hospitals and end consumers across China through this sales
network.





Locations
of Our Independent Distributors' Sales Offices in China.










11




Research
and Development





Old
Renhuang established a R&D center in 2002 in Harbin City, China which was
transferred to Renhuang China in 2006. Currently, our center employs
30 researchers, engineers and technicians working in the following
functions:





—
            Comprehensive
      testing


—
            New
      product development


—
            Nutraceutical
      and healthy food development


—
            Standard
      extracts development


—
            Biopharmaceutical
      products development


—
            Mid-scale
      testing


—
            Diagnostic
      reagent development


—
            Product
      approval submission





Through
our research control and relative dominant position related to our Acanthopanax
products, we believe we are on the verge of positioning Acanthopanax as an
independent segment in the Chinese drug industry. In order to achieve this goal,
we plan on building an Acanthopanax base, to become the largest GMP approved
Acanthopanax base in China, including six parts: (1) wild Acanthopanax
protection; (2) research; (3) seeding; (4) cultivating; (5) processing; and (6)
exporting.





In
addition, we plan to continually upgrade our products by using follow-up
research projects. This continued development focuses on the following three
areas: (1) the development of biotech products, with the focus on practical
applications of lysozyme and hyperoxide mutase, and the research and development
of gene engineering drugs; (2) the research and development of Chinese
traditional medicine products, including but not limited to additional use of
Acanthopanax and Shizandra Berry; and (3) research and development of Western
drugs for generic production, where we are able to complete the generational
replacement of traditional drugs in a short period of time.





We
utilize our marketing network system to provide periodic market feedback
information, market demand information, evaluation of new products inside and
outside of China, domestic and foreign authority research topics and product
technology feedback information.




Research
Center and Mid-Testing Base





Formed by
different labs, these research and mid-testing facilities are simulating the
assembly lines.





Renhuang
Bio-Tech Drugs and Healthcare Products Research Center





This
facility is mainly focused on the research and development of bio-tech drugs,and
healthcare products.





Post-doc
Research Workstation





The major
task is to do research and development on Acanthopanax and other North-China
medical products and to develop medicine qualified to international standard.
This unit also performs research and development on gene engineering drugs, like
tumor Chalone.





12




Industry
Analysis





The
Current Chinese Pharmaceutical Market





Traditionally,
the pharmaceutical market is defined based on the different medical usage and is
generally split into the prescription drug market and non-prescription medicine
market (“OTC”).





The
annual revenue of the medicine market in China is estimated to be approximately
1 trillion RMB (US$ 140 billion) in 2008.





There are
about 2,000 pharmaceutical companies with GMP Certificates in China, Renhuang is
one of the pharmaceutical companies that has obtained the GMP Certificate under
strict control of the Chinese government. As our market grows, we anticipate
increased production volume through acquisitions and/or additional production
facilities.





Our first
and primary target market is China, where we believe a growing middle class with
demands for improved healthcare has created a sustainable need for quality
healthcare products. Our secondary market in the long-term future is the United
States and other regions of the world.





Most of
the recognized brands in China are manufactured by multi-national drug companies
with higher market share than domestic brands. Based on our research, there are
approximately 2,000 drug companies with GMP certificates, producing a variety of
traditional and modern Chinese medical products. Furthermore, Chinese drug
companies produce 300 different types of biotech products including vaccines,
antiserum, blood products, and diagnosing reagents for internal and external
use.









—Market
Shares of various pharmaceutical products




The
Current State of the Biotech Industry in China





The
biotech industry in China has undergone fundamental improvements in recent
years. China’s biological product market, which includes gene engineering drugs,
vaccines, antibodies, and blood products, surpassed 30.3 billion RMB in 2005,
39.1 billion RMB in 2006, 44.6 billion RMB in 2007, and 53 billion RMB in
2008





13


In order
to accelerate the development of the PRC’s domestic biotech industry, the
Chinese government has invested in biotech research and development. Biotech
engineering and bio-drugs are making progress and a series of key technologies
have been built. Tens of gene drugs are fast approaching the area of practical
use and the Chinese biotech R&D industry is rapidly becoming more mature and
competitive.





Competition





We are subject to intense
competition.  Some of our competitors have greater financial
resources, larger staff, and better established market recognition than
us.  Below are lists of Chinese companies that we view as our
competitors in each of our product series.





Acanthopanax Product Series
Competitors





Hongdoushan Pharmaceuticals, with
      main Acanthopanax products of tablets, and with approximately 7% of the
      market share of Acanthopanax
tablets.





Wangdashang Pharmaceuticals, with
      main Acanthopanax products of tablets and syrup, and with approximately 5%
      and 2% of the market share of Acanthopanax tablets and syrup,
      respectively.





Lianhuahu Pharmaceuticals, with
      main Acanthopanax products of ointment and raw product, and with
      approximately 15% and 10% of the market share of Acanthopanax ointment and
      raw products respectively.





Harbin Shengyuan Pharmaceuticals, with main Acanthopanax product of
      Acanthopanax ointment, and with approximately 10% of the market share of
      Acanthopanax ointment.




Shark Power Healthcare Series
Competitors





Beijing Saishali Company, with
      approximately 17% market
share


Shantou Xianle Pharmaceuticals,
      with approximately 8% market
share


Shangai Zhongyang Donghai
      Pharmaceuticals, with approximately 5% market
  share





Traditional Medical Products
Competitors





Compound Yang Jiao
Tablets





Harbin Sanjing North
      Pharmaceuticals, with approximately 16% market
  share


Harbin Huarui Pharmaceuticals,
      with approximately 15% market
share


Harbin Mingmu Pharmaceuticals,
      with approximately 9% market
share




14




Tianma
Pills





Sigpore Xinri Pharmaceuticals,
      with approximately 20% market
share


Guizhou Yibai Pharmaceuticals,
      with approximately 18% market
share


Sanjiu Pharmaceuticals, with
      approximately 20% market
share





Powder For Restoring Pulse
Beat





Gansu Foci Pharmaceuticals, with
      approximately 12% market
share


Hubei Meibao Pharmaceuticals,
      with approximately 8% market
share


Nanning Weiwei Pharmaceuticals,
      with approximately 6% market
share





Lysozyme
Products Competitors





We
believe there are few companies with the ability to produce lysozyme products on
a large scale. Thus, the competition is scarce.





Competitive
Strengths





Experienced
Management Team





Our
management team has over 35 years of experience in the pharmaceutical industry
combined, which, when compared to Old Renhuang’s historical numbers, generated
historical annual growth in both sales and profits.





Through
the acquisition of DFH in 2003, Old Renhuang obtained most of the wild resources
of Acanthopanax in Heilongjiang Province.  As of May 1, 2006, Old
Renhuang transferred all acquired operations of DFH to Renhuang
China.  We believe that we have a relatively dominant position in
terms of resource control. We estimate that our cost of production is 30% lower
than the competition.





In
addition to our advantageous access to wild Acanthopanax sources, we believe
that we have the following competitive strengths related to
Acanthopanax:





Resources
Cultivation





Current
wild Acanthopanax resources may not be able to fulfill the rapidly growing
demand. Therefore, we have started to cultivate Acanthopanax in woodland areas.
Our cultivated Acanthopanax achieves, in all material respects, the same effects
as wild Acanthopanax, mainly due to our use of wild Acanthopanax seeds and other
production methods as well as its extraordinarily favorable climate conditions
in Heilongjiang Province.




15




Lower
Production Costs





We have
successfully developed new extraction technology during the process of
cultivating and producing Acanthopanax. Based on our estimates, we believe that
our new technology will lead to production costs that will be lower than our
competitors.





We
believe that our Shark Power Healthcare products have the following competitive
strengths:





State
Drug Administration Approval





Our Shark
Power Healthcare products have received Good Manufacturing Practice (“GMP”)
certificates from the State Drug Administration (“SDA”). As most healthcare
products produced in China have not obtained GMP certificates, our Shark Power
Healthcare products have a strong competitive advantage. Our Shark Power
Healthcare products are also distributed through hospital channels, which is not
the case for most other similar health care products.





Lower
Production Costs





The
retail price of Shark Power Healthcare products has historically been lower than
the price of similar products from our competitors due to our lower raw material
costs.  We purchase raw materials indirectly from Australia at prices
which we believe are as much as 20% lower than the cost of these materials when
obtained from coastal areas in China, where most competitors purchase their
materials.





In
addition, we believe our business possesses the following competitive
strengths:





The ability to upgrade our
      products by using our follow-up research projects enables us to continue
      our product development.


We have developed an independent
      research cooperation system, which can provide support to our research and
      development of new products.


We have been awarded outstanding
      levels of status by provincial, city and regional
      governments.


We employ an experienced research
      team of scientists.


Through efficiency and our
      production facilities, we believe our production costs are on average 5%
      to 10% lower than those of our
  competitors.




Official
Accomplishments





The Chinese government has
      appraised us as “The Best Quality and Credit Company”, “The Company with
      The Best Social Image”, and “The Most Trustful Consumer Products
      Company”.


Our Lysozyme and Hyperoxide
      mutase projects have been included into the most important national level
      project in the State Scientific
  Administration.


Biotech drug garden has been
      included into the national transforming projects of North Eastern China
      heavy industry base, and in the projects which may obtain zero interests
      loans from the Chinese
government.




16




Customers




Our
primary independent sales distributors are listed in the table below. These
sales distributors account for more than 5% of our revenue. The revenue figures
listed below are revenues received from these distributors before any reduction
for any volume rebates we may have paid to these distributors.




Customer
                              
                              Revenuefor FYEOctober 31,2008,BeforeRebate(RMB)
                              
                              Revenuefor FYEOctober31, 2008,BeforeRebate(USD)
                              
                              % ofTotalRevenueBaojin
      Yang
                              
                              
                              31,581,025
                              
                              4,511,575
                              
                              
                              10.49
                              %Gang
      Hua
                              
                              
                              31,254,600
                              
                              4,464,943
                              
                              
                              10.39
                              %Hui
      Zhao
                              
                              
                              27,295,538
                              
                              3,899,363
                              
                              
                              9.07
                              %Jing
      Hua
                              
                              
                              16,440,235
                              
                              2,348,605
                              
                              
                              5.46
                              %Hongtao
      Zhang
                              
                              
                              16,717,400
                              
                              2,388,200
                              
                              
                              5.56
                              %Xuchang
      Li
                              
                              
                              17,565,717
                              
                              2,509,388
                              
                              
                              5.84
                              %Sijiang
      Qin
                              
                              
                              16,493,200
                              
                              2,356,171
                              
                              
                              5.48
                              %Jianjun
      Wu
                              
                              
                              16,791,873
                              
                              2,398,839
                              
                              
                              5.58
                              %Yong
      Hua
                              
                              
                              15,918,671
                              
                              2,274,096
                              
                              
                              5.29
                              %Xue
      Qin
                              
                              
                              15,870,769
                              
                              2,267,253
                              
                              
                              5.27
                              %




Employees





We employ
more than 600 full time individuals, including 150 employees in managerial
positions, 60 employees as sales managers, 12 R&D managers among 30
employees in our R&D department, and more than 400 general workers. We also
utilize approximately 22 independent sales distributors in various sales
offices that work as independent contractors.





Government
Regulation





The
State Drug Administration





The SDA
of China has set up a classification administrative system in 1999 for
prescription and OTC drugs. Since then, the SDA has issued a series of
guidelines on the interpretation of the new classification system for labeling,
usage instructions and packaging of OTC products. The SDA currently requires
that pharmaceutical manufacturers clearly label drugs for OTC sales and
distinguish them from those, under SDA regulations, acceptable to be sold in
hospitals.  We have instituted  policies that we believe
comply with SDA regulations. We successfully passed all GMP investigations by
SDA and received approval certificates.




17




In
September 2005, Old Renhuang received a certification for exporting products by
Entry-Exit Inspection and Quarantine Administration, and received a
self-reporting inspection registration certificate. In May 2006, all
certificates were transferred to Renhuang China.




Environmental
Matters





We have
not been required to perform any investigation or clean-up activities, nor have
we been subject to any environmental claims. There can be no assurance, however,
that this will remain the case in the future.





Trade
Names and Service Marks





We do not
currently own any Trade Names, Trade Marks or Service Marks.





ITEM
1A – RISK FACTORS





Cautionary
Statement Regarding Future Results, Forward-Looking Information And Certain
Important Factors





In this
report we make, and from time to time we otherwise make, written and oral
statements regarding our business and prospects, such as projections of future
performance, statements of management’s plans and objectives, forecasts of
market trends, and other matters that are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Statements containing the words or
phrases “will likely result,” “are expected to,” “will continue,” “is
anticipated,” “estimates,” “projects,” “believes,” “expects,” “anticipates,”
“intends,” “target,” “goal,” “plans,” “objective,” “should” or similar
expressions identify forward-looking statements, which may appear in documents,
reports, filings with the Securities and Exchange Commission, news releases,
written or oral presentations made by officers or other representatives made by
us to analysts, stockholders, investors, news organizations and others, and
discussions with management and other of our representatives. For such
statements, we claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of
1995.




Our
future results, including results related to forward-looking statements, involve
a number of risks and uncertainties. No assurance can be given that the results
reflected in any forward-looking statements will be achieved. Any
forward-looking statement speaks only as of the date on which such statement is
made. Our forward-looking statements are based upon assumptions that are
sometimes based upon estimates, data, communications and other information from
suppliers, government agencies and other sources that may be subject to
revision. Except as required by law, we do not undertake any obligation to
update or keep current either (i) any forward-looking statement to reflect
events or circumstances arising after the date of such statement, or
(ii) the important factors that could cause our future results to differ
materially from historical results or trends, results anticipated or planned by
us, or which are reflected from time to time in any forward-looking
statement.





In
addition to other matters identified or described by us from time to time in
filings with the SEC, there are several important factors that could cause our
future results to differ materially from historical results or trends, results
anticipated or planned by us, or results that are reflected from time to time in
any forward-looking statement. Some of these important factors, but not
necessarily all important factors, include the following:




18




Risks
Related To Our Business, Operations and Industry




Current economic conditions may
adversely impact demand for our products, reduce access to credit and cause our
customers and others with which we do business to suffer financial hardship, all
of which could adversely impact our business, results of operations, financial
condition and cash flows.




Our
business, financial condition and results of operations have and may continue to
be affected by various economic factors. The worldwide economy is undergoing a
period of slowdown and the future economic environment may continue to be less
favorable than that of recent years. This slowdown has, and could further lead
to, reduced consumer and business spending in the foreseeable future, including
by our customers. Reduced access to credit has and may continue to adversely
affect the ability of consumers to purchase our fire safety products and
systems.  In addition, economic conditions, including decreased access
to credit, may result in financial difficulties leading to restructurings,
bankruptcies, liquidations and other unfavorable events for our customers,
suppliers and other service providers. If such conditions continue or further
deteriorate, our industry, business and results of operations may be severely
impacted.





We will need to raise additional
capital to expand our business.





For the
foreseeable future, we will fund all of our operations and capital expenditures
from cash on hand and potential future internally generated cash flow.
Currently, we believe we have sufficient cash on hand to fund our operations and
planned expansions. However, changes may occur that would consume our available
capital, including changes in and progress of our development activities,
acquisitions of additional candidates and changes in regulation. We will then
need to seek additional sources of financing, which may not be available on
favorable terms, if at all. If we do not succeed in raising additional funds on
acceptable terms, we may be unable to complete our expansion and future growth.
In addition, we could be forced to discontinue product development, reduce or
forego sales and marketing efforts and forego attractive business opportunities.
Any additional sources of financing will likely involve the issuance of our
equity securities, which will have a dilutive effect on our
stockholders.





Our
profitability is limited.





We will
need to generate significant revenues in order to achieve and maintain
profitability. We may not be able to generate these revenues or achieve
profitability in the future. Our failure to achieve or maintain profitability
could negatively impact our business, operating results and financial
conditions.





We
may be unable to obtain and maintain the necessary Chinese or worldwide
regulatory approvals to commercialize our products.





To
commercializecertain of our current
and future products, we require approvals from SDA and any FDA-equivalent
regulatory authorities in foreign jurisdictions. Currently, we do not sell our
products to the United States, but if we plan to commercialize our products to
the U.S., we will require FDA approval for some of our products. To apply for
approval, we must submit to the FDA a New Drug Application, or NDA,
demonstrating that the product candidate is safe for humans and effective for
its intended use. This demonstration requires significant research and animal
testing, which are referred to as pre-clinical studies, as well as human
testing, which are referred to as clinical trials. Satisfaction of the FDA’s
regulatory requirements typically takes many years, depending upon the type,
complexity and novelty of the product candidate and requires substantial
resources for research, development and testing. We cannot predict whether our
research and clinical approaches will result in drugs that the FDA or
FDA-equivalent in other jurisdictions consider safe for humans and effective for
indicated uses. The FDA has substantial discretion in the drug approval process
and may require us to conduct additional pre-clinical and clinical testing or to
perform post-marketing studies. The approval process may also be delayed by
changes in government regulation, future legislation or administrative action or
changes in FDA policy that occur prior to or during our regulatory review.
Delays in obtaining regulatory approvals may:




19




delay commercialization of, and
      our ability to derive product revenues from, our product
      candidates;


impose costly procedures on us;
      and




diminish any competitive
      advantages that we may otherwise
enjoy.




In
foreign jurisdictions, we must receive approval from the appropriate regulatory
authorities before we can commercialize any drugs. Foreign regulatory approval
processes generally include all of the risks associated with the FDA approval
procedures described above.





We cannot
guarantee that we will maintain and receive the approvals necessary to
commercialize our current and future products for sale in China, United States
or elsewhere.





Clinical
trials are very expensive, time-consuming and difficult to design and
implement.





Human
clinical trials are very expensive and difficult to design and implement, in
part because they are subject to rigorous regulatory requirements. The clinical
trial process is also time consuming. We estimate that clinical trials of our
product candidate will take at least several years to complete. Furthermore,
failure can occur at any stage of the trials, and we could encounter problems
that cause us to abandon or repeat clinical trials. The commencement and
completion of clinical trials may be delayed by several factors,
including:





unforeseen safety
      issues;


determination of dosing
      issues;


lack of effectiveness during
      clinical trials;


slower than expected rates of
      patient recruitment;


inability to monitor patients
      adequately during or after treatment;
and


inability or unwillingness of
      medical investigators to follow our clinical
    protocols.





In
addition, we, SDA, FDA or FDA-equivalent institutions in foreign jurisdictions
may suspend our clinical trials at any time if it appears that we are exposing
participants to unacceptable health risks or if the regulatory bodies find
deficiencies in our Investigational New Drug, or IND, submissions or the conduct
of these trials. Therefore, we cannot predict with any certainty the schedule
for future clinical trials.





The results of our clinical trials
may not support our product candidate claims.





Even if
our clinical trials are completed as planned, we cannot be certain that their
results will support our product candidate claims. Success in pre-clinical
testing and early clinical trials does not ensure that later clinical trials
will be successful, and we cannot be sure that the results of later clinical
trials will replicate the results of prior clinical trials and pre-clinical
testing. The clinical trial process may fail to demonstrate that our product
candidates are safe for humans and effective for indicated uses. This failure
would cause us to abandon a product candidate and may delay development of other
product candidates.




20




Physicians, patients and other end
consumer may abandon existing or choose not to accept and use our new
drugs.





Physicians
and patients may not accept and use our products. Acceptance and use of our
product will depend upon a number of factors including:





perceptions by members of the
      health care community, including physicians, about the safety and
      effectiveness of our
products;


cost-effectiveness of our product
      relative to competing products;
and




effectiveness of marketing and
      distribution efforts by us and our licensees and distributors, if
      any.





Because
we expect sales of our current and future products to generate substantially all
of our product revenues for the foreseeable future, the failure to find market
acceptance would materially harm our business and results of
operations.





Our drug-development program depends
upon third-party research scientists who are not subject to our
control.





We depend
upon independent investigators and collaborators, such as universities and
medical institutions, to conduct our pre-clinical and clinical trials under
agreements with us. These collaborators are not our employees and we cannot
control the amount or timing of resources that they devote to our programs.
These investigators may not assign as great a priority to our programs or pursue
them as diligently as we would if we were undertaking such programs ourselves.
If outside collaborators fail to devote sufficient time and resources to our
drug-development programs, or if their performance is substandard, the approval
of our applications, if any, and our introduction of new drugs, if any, will be
delayed. These collaborators may also have relationships with other commercial
entities, some of which may compete with us. If our collaborators assist our
competitors at our expense, our competitive position and business could be
materially and adversely affected.





We
need to increase our selling, marketing and distributing network.





We need
significant capital expenditures, time and management resources to market our
products and to establish and develop an in-house marketing and sales force with
technical expertise. There can be no assurance that we will be able to
establish, maintain or develop in-house sales and distribution capabilities. To
the extent that we depend on third parties for marketing and distribution, any
revenues we receive will depend upon the efforts of such third parties, and
there can be no assurance that such efforts will be successful.




21




If we cannot compete successfully for
market share against other similar product oriented companies, we may not
achieve sufficient product revenues and our business will
suffer.





The
market for our product candidates is characterized by intense competition and
rapid technological advances. We will compete with a number of existing and
future drugs and therapies developed, manufactured and marketed by others.
Existing or future competing products may provide greater therapeutic
convenience or clinical or other benefits for a specific indication than our
products, or may offer comparable performance at a lower cost. If our products
fail to capture and maintain market share, we may not achieve sufficient product
revenues and our business will suffer.





We will
compete against fully integrated pharmaceutical companies and smaller companies
that are collaborating with larger pharmaceutical companies, academic
institutions, government agencies and other public and private research
organizations. Many of these competitors have either alone or together with
their collaborative partners, operate larger research and development programs
or have substantially greater financial resources than we do, as well as
significantly greater experience in:





developing
      drugs;


undertaking pre-clinical testing
      and human clinical trials;


obtaining regulatory approvals of
      drugs;


formulating and manufacturing
      drugs; and


launching, marketing and selling
      drugs.





Developments
by competitors may render our products or technologies obsolete or
non-competitive.





The
biotechnology and pharmaceutical industries are intensely competitive and
subject to rapid and significant technological change. A large number of
companies are pursuing the development of pharmaceuticals that target the same
diseases and conditions that we are targeting. We face competition from
pharmaceutical and biotechnology companies in China and other countries. In
addition, companies pursuing different but related fields represent substantial
competition. Many of these organizations competing with us have substantially
greater capital resources, larger research and development staffs and
facilities, longer drug development history in obtaining regulatory approvals
and greater manufacturing and marketing capabilities than we do. These
organizations also compete with us to attract qualified personnel and parties
for acquisitions, joint ventures or other collaborations.





If we fail to adequately protect or
enforce our intellectual property, the value of our intellectual property rights
would diminish and our business would be harmed.





Our
success, competitive position and future revenues will depend in part on our
ability and the abilities of our licensors to obtain and maintain patent
protection for our products, methods, processes and other technologies, to
preserve our trade secrets, to prevent third parties from infringing on our
proprietary rights and to operate without infringing the proprietary rights of
third parties.





Our
success is partly dependent upon the skills, knowledge and experience of our
scientific and technical personnel, our consultants and advisors as well as our
licensors and contractors. To help protect our proprietary know-how and our
product developments for which patents may be unobtainable or difficult to
obtain, we rely on trade secret protection and confidentiality agreements. To
this end, it is our policy to require all of our employees, consultants,
advisors and contractors to enter into agreements which prohibit the disclosure
of confidential information and, where applicable, require disclosure and
assignment to us of the ideas, developments, discoveries and inventions
important to our business. These agreements may not provide adequate protection
for our trade secrets, know-how or other proprietary information in the event of
any unauthorized use or disclosure or the lawful development by others of such
information. If any of our trade secrets, know-how or other proprietary
information is disclosed, the value of our trade secrets, know-how and other
proprietary rights would be significantly impaired and our business and
competitive position would suffer.




22




We may not successfully manage our
growth.





Our
success will depend upon the expansion of our operations and the effective
management of our growth, which will place a significant strain on our
management and on our administrative, operational and financial resources. To
manage this growth, we must expand our facilities, augment our operational,
financial and management systems and hire and train additional qualified
personnel. If we are unable to manage our growth effectively, our business would
be harmed.





We
give no assurances that any plans for future expansion will be
implemented.





Under our
current business plan, we intend to expand our production of our current
products. However, we have not made any definitive plans or signed any binding
agreements to implement this expansion strategy. We may decide to use operating
income to finance these expenditures, which would reduce our operating
capital.





We
have a limited operating history and limited historical financial information
upon which you may evaluate our performance.





We began
our operations in 2006 and continue to face risks in a growth industry. We may
not successfully address these risks and uncertainties or successfully implement
our operating strategies. If we fail to do so, it could materially harm our
business to the point of having to cease operations and could impair the value
of our common stock to the point investors may lose their entire investment.
Even if we accomplish these objectives, we may not generate positive cash flows
or the profits we anticipate in the future.





We will face substantial
competition, some of which may be better capitalized and more experienced than
us.





We face
competition in the pharmaceutical and medical product industry. Although we view
ourselves in a favorable position vis--vis our competition, some of the other
pharmaceutical and medical product companies that sell into our markets may be
more successful than us and/or have more experience and financial resources than
we do. This additional experience and financial resources may enable our
competitors to produce more effective pharmaceuticals and sell their product
with more success than we are able to, which would decrease our
sales.





We rely on key executive officers and
scientific advisors, and their knowledge of our business and technical expertise
would be difficult to replace.





We are
highly dependent on our principal scientific, regulatory and medical advisors.
We do not have “key person” life insurance policies for any of our officers. The
loss of the technical knowledge and management and industry expertise of any of
our key personnel could result in delays in product development, loss of
customers and sales and diversion of management resources, which could adversely
affect our operating results.





23


Risks
Related to Doing Business in China





Our
manufacturing plants are located in China and our pharmaceutical and medical
products production, sale and distribution are subject to Chinese
regulation.





Economic
reforms adopted by the Chinese government have had a positive effect on the
economic development of the country, but the government could change these
economic reforms or any of the legal systems at any time. This could either
benefit or damage our operations and profitability. Some changes that could have
this effect are: i) level of government involvement in the economy; ii) control
of foreign exchange; iii) methods of allocating resources; iv) balance of
payment positions; v) international trade restrictions; and vi)
international conflict. Additionally, as a manufacturer of pharmaceutical and
medical products located in China, we are a state-licensed company and facility
and subject to Chinese regulations and laws. The Chinese government has been
active in regulating the pharmaceutical industry. If we were to lose our
state-licensed status we would no longer be able to manufacture pharmaceuticals
in China, which is our sole operation.





We
depend upon governmental laws and regulations that may be changed in ways that
will harm our business.





Our
business and products are subject to government regulations mandating the
manufacturing of pharmaceuticals in China and other countries. Changes in the
laws or regulations in China, or other countries we sell into, that govern or
apply to our operations could have a materially adverse effect on our business.
For example, the law could change so as to prohibit the use of certain
pharmaceuticals. If one of our pharmaceuticals or medical products are
prohibited, this change would reduce our productivity of that
product.





The
Chinese government exerts substantial influence over the manner in which we must
conduct our business activities.





China
only recently has permitted provincial and local economic autonomy and private
economic activities. The Chinese government has exercised and continues to
exercise substantial control over virtually every sector of the Chinese economy
through regulation and state ownership. Our ability to operate in China may be
harmed by changes in its laws and regulations, including those relating to
taxation, import and export tariffs, pharmaceutical regulations, and other
matters. We believe that our operations in China are in material compliance with
all applicable legal and regulatory requirements. However, the central or local
governments of these jurisdictions may impose new, stricter regulations or
interpretations of existing regulations that would require additional
expenditures and efforts on our part to ensure our compliance with such
regulations or interpretations.





Accordingly,
government actions in the future, including any decision not to continue to
support recent economic reforms and to return to a more centrally planned
economy or regional or local variations in the implementation of economic
policies, could have a significant effect on economic conditions in China or
particular regions thereof, and could require us to divest ourselves of any
interest we then hold in Chinese properties or joint ventures.


24


Future
inflation in China may inhibit our activity to conduct business in
China.





In recent
years, the Chinese economy has experienced periods of rapid expansion and high
rates of inflation. During the past ten years, the rate of inflation in China
has been as high as 20.7% and as low as -2.2%. These factors have led to the
adoption by Chinese government, from time to time, of various corrective
measures designed to restrict the availability of credit or regulate growth and
contain inflation. While inflation has been more moderate since 1995, high
inflation may cause Chinese government to impose controls on credit and/or
prices, or to take other action, which could inhibit economic activity in China,
and thereby harm the market for our products.





Restrictions
on currency exchange may limit our ability to receive and use our revenues
effectively.





The
majority of our revenues will be settled in Renminbi and U.S. Dollars, and any
future restrictions on currency exchanges may limit our ability to use revenue
generated in Renminbi to fund any future business activities outside China or to
make dividend or other payments in U.S. dollars. Although the Chinese government
introduced regulations in 1996 to allow greater convertibility of the Renminbi
for current account transactions, significant restrictions still remain,
including primarily the restriction that foreign-invested enterprises may only
buy, sell or remit foreign currencies after providing valid commercial
documents, at those banks in China authorized to conduct foreign exchange
business. In addition, conversion of Renminbi for capital account items,
including direct investment and loans, is subject to governmental approval in
China, and companies are required to open and maintain separate foreign exchange
accounts for capital account items. We cannot be certain that the Chinese
regulatory authorities will not impose more stringent restrictions on the
convertibility of the Renminbi.




The
value of our securities will be affected by the foreign exchange rate between
U.S. dollars and Renminbi.





The value
of our common stock will be affected by the foreign exchange rate between U.S.
dollars and Renminbi, and between those currencies and other currencies in which
our sales may be denominated in the future. For example, to the extent that we
need to convert U.S. dollars into Renminbi for our operational needs and should
the Renminbi appreciate against the U.S. dollar at that time, our financial
position, the business of the Company, and the price of our common stock may be
harmed. Conversely, if we decide to convert our Renminbi into U.S. dollars for
the purpose of declaring dividends on our common stock or for other business
purposes and the U.S. dollar appreciates against the Renminbi, the U.S. dollar
equivalent of our earnings from our subsidiaries in China would be
reduced.





Our business is largely subject to
the uncertain legal environment in China and your legal protection could be
limited.





The
Chinese legal system is a civil law system based on written statutes. Unlike
common law systems, it is a system in which precedents set in earlier legal
cases are not generally used. The overall effect of legislation enacted over the
past 20 years has been to enhance the protections afforded to foreign invested
enterprises in China. However, these laws, regulations and legal requirements
are relatively recent and are evolving rapidly, and their interpretation and
enforcement involve uncertainties. These uncertainties could limit the legal
protections available to foreign investors, such as the right of foreign
invested enterprises to hold licenses and permits such as requisite business
licenses. In addition, some of our executive officers and our directors may be
residents of China and not of the United States, and substantially all the
assets of these persons are located outside the U.S. As a result, it could be
difficult for investors to affect service of process in the United States, or to
enforce a judgment obtained in the United States against us or any of these
persons.


25


Risks
Related to Shares of Our Common Stock





Our
common stock has been thinly traded and we cannot predict the extent to which a
trading market will develop.





Our
common stock is quoted on the Pink Sheet Electronic Over the Counter Market (the
“Pink Sheets”), an electronic quotation service for securities traded
over-the-counter. Our common stock is thinly traded compared to larger, more
widely known companies. Thinly traded common stock can be more volatile than
common stock trading in an active public market. We cannot predict the extent to
which an active public market for our common stock will develop or be
sustained.





Because
we are subject to the “penny stock” rules, the level of trading activity in our
stock may be reduced.





Our
common stock is traded on the Pink Sheets.   Broker-dealer
practices in connection with transactions in “penny stocks” are regulated by
certain penny stock rules adopted by the Securities and Exchange Commission.
Penny stocks, like shares of our common stock, generally are equity securities
with a price of less than $5.00, other than securities registered on certain
national securities exchanges or quoted on NASDAQ. The penny stock rules require
a broker-dealer, prior to a transaction in a penny stock not otherwise exempt
from the rules, to deliver a standardized risk disclosure document that provides
information about penny stocks and the nature and level of risks in the penny
stock market. The broker-dealer also must provide the customer with current bid
and offer quotations for the penny stock, the compensation of the broker-dealer
and its salesperson in the transaction, and, if the broker-dealer is the sole
market maker, the broker-dealer must disclose this fact and the broker-dealer's
presumed control over the market, and monthly account statements showing the
market value of each penny stock held in the customer's account. In addition,
broker-dealers who sell these securities to persons other than established
customers and “accredited investors” must make a special written determination
that the penny stock is a suitable investment for the purchaser and receive the
purchaser's written agreement to the transaction. Consequently, these
requirements may have the effect of reducing the level of trading activity, if
any, in the secondary market for a security subject to the penny stock rules,
and investors in our common stock may find it difficult to sell their
shares.





ITEM
1B – UNRESOLVED STAFF COMMENTS





None.





ITEM
2 - PROPERTIES





Our
executive offices in the United States are provided to us at no cost at the
offices of one of our shareholders, Viking Investments USA, Inc., which are
located at 65 Broadway, 7th Floor,
New York, New York. The fair market value of the office space we utilize is
approximately $2,000 per month.





Our
operations in China are conducted out of our offices located at No. 281 Taiping
Road, Taiping District Harbin, Heilongjiang Province, 150050, P.R. China. These
offices are owned by Old Renhuang and we rent the space pursuant to a one year
lease. We currently lease a total of 105,416 square feet, with approximately
15,000 square feet used for executive offices and approximately 90,000 square
feet used for production and inventory.


26


ITEM
3 - LEGAL PROCEEDINGS





We are
not a party to, or threatened by, any litigation or procedures.





ITEM
4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS





There
have been no events that are required to be reported under this
Item.




PART
II





ITEM
5 - MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES





Market
Information





Our
common stock is currently quoted on the Pink Sheet OTC market of the National
Association of Securities Dealers, Inc., under the symbol “RHGP.” Our common
stock is only traded on a limited or sporadic basis and should not be deemed to
constitute an established public trading market. There is no assurance that
there will be liquidity in the common stock.





The
following table sets forth the high and low bid information for each quarter
within the two most recent fiscal years, as provided by the Over-The-Counter
Bulletin Board. The information reflects prices between dealers, and does not
include retail markup, markdown, or commission, and may not represent actual
transactions.





Quarter
      Ended
                      
                      High
                      
                      LowJanuary
      31, 2007
                      
                      
                      3.95
                      
                      3.90April
      30, 2007
                      
                      
                      3.10
                      
                      3.10July
      31, 2007
                      
                      
                      2.50
                      
                      2.50October
      31, 2007
                      
                      
                      2.28
                      
                      2.25January
      31, 2008
                      
                      
                      1.65
                      
                      1.60April
      30, 2008
                      
                      
                      0.82
                      
                      0.82July
      31, 2008
                      
                      
                      1.06
                      
                      1.06October
      31, 2008
                      
                      
                      0.65
                      
                      0.65January
      31, 2009
                      
                      
                      0.20
                      
                      0.20April
      30, 2009
                      
                      
                      0.20
                      
                      0.20June
      9, 2009
                      
                      
                      0.50
                      
                      0.50





The
Securities Enforcement and Penny Stock Reform Act of 1990 requires additional
disclosure relating to the market for penny stocks in connection with trades in
any stock defined as a penny stock. The Commission has adopted regulations that
generally define a penny stock to be any equity security that has a market price
of less than $5.00 per share, subject to a few exceptions that we do not meet.
Unless an exception is available, the regulations require the delivery, prior to
any transaction involving a penny stock, of a disclosure schedule explaining the
penny stock market and the risks associated therewith.


27


Holders




As of
August 24, 2009, there were 37,239,536 shares of our common stock issued
and outstanding held by 80 holders of record.





Dividend
Policy





We do not
expect to pay any dividend in the foreseeable future. We intend to apply our
earnings, if any, in expanding our operations and related activities. The
payment of cash dividends on our common stock in the future will be at the
discretion of the Board of Directors and will depend upon such factors as
earnings levels, capital requirements, our financial condition and other factors
deemed relevant by the Board of Directors.




ITEM
6 – SELECTED FINANCIAL DATA





Not
required.





ITEM
7 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATION





Disclaimer
Regarding Forward Looking Statements





Our
Management’s Discussion and Analysis or Plan of Operations contains not only
statements that are historical facts, but also statements that are
forward-looking (within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934). Forward-looking
statements are, by their very nature, uncertain and risky. These risks and
uncertainties include international, national and local general economic and
market conditions; demographic changes; our ability to sustain, manage, or
forecast growth; our ability to successfully make and integrate acquisitions;
raw material costs and availability; new product development and introduction;
existing government regulations and changes in, or the failure to comply with,
government regulations; adverse publicity; competition; the loss of significant
customers or suppliers; fluctuations and difficulty in forecasting operating
results; changes in business strategy or development plans; business
disruptions; the ability to attract and retain qualified personnel; the ability
to protect technology; and other risks that might be detailed from time to time
in our filings with the Securities and Exchange Commission.





Although
the forward-looking statements in this Annual Report on Form 10-K reflect the
good faith judgment of our management, such statements can only be based on
facts and factors currently known by them. Consequently, and because
forward-looking statements are inherently subject to risks and uncertainties,
the actual results and outcomes may differ materially from the results and
outcomes discussed in the forward-looking statements. You are urged to carefully
review and consider the various disclosures made by us in this report and in our
other reports as we attempt to advise interested parties of the risks and
factors that may affect our business, financial condition, and results of
operations and prospects.





Overview





As of
March 3, 2006, we discontinued our previous operations as a company specializing
in the providing of home financing through the brokerage of residential home
loans. On September 7, 2006, we acquired 100% of the issued and outstanding
shares of Harbin Renhuang Pharmaceutical Company Limited, a corporation
incorporated under the laws of the British Virgin Island, (‘‘BVI’’), whose only
assets are 100% of the equity of Harbin Renhuang Pharmaceutical Co. Ltd.,
incorporated under the laws of the Peoples Republic of China (“Renhuang China”)
mainly focused on the research, production and sales of traditional Chinese and
Western medical and bio-pharmaceutical products in China.


28


On May 1,
2006, Harbin Renhuang Pharmaceutical Stock Co. Ltd., (“Old Renhuang”)
transferred the majority of its operating assets to Renhuang China, with the
exception of the buildings Old Renhuang owns (including where we rent our office
space and production facilities), and Old Renhuang’s account receivables,
inventories and other assets with zero or insignificant value. The principal
business activities of Renhuang remained unchanged. On March 3, 2006 Renhuang
Medicine for Animals Co. Ltd. a company controlled by Mr. Li Shaoming, invested
25 million RMB (about US $3.3 million) in cash in Renhuang China.




Our
pharmaceutical products are distributed through our approximately 22 independent
sales distributors. These distributors have more than 70 sales offices with more
than 3,000  sales people. Upon the effectiveness of the Merger, we
adopted the business of Renhuang China, which we have continued as our sole line
of business.





Upon
closing of the Merger, BVI and its subsidiary Renhuang China
became our wholly owned subsidiaries. The Former stockholders of BVI own
approximately 85% of our issued and outstanding common stock.





Reverse
Merger





Our
acquisition of the BVI company and its subsidiary Renhuang China was
accounted for as a reverse merger, because, after giving effect to the
share exchanges, the former stockholders of BVI hold a majority of our
outstanding common stock on a voting and fully diluted basis. As a result of the
share exchanges, Renhuang was deemed to be the acquirer for accounting purposes.
Accordingly, the financial statements presented are those of Renhuang China for
all periods prior to our acquisition of the BVI company on September 7, 2006,
and the financial statements of the consolidated companies from the acquisition
date forward.





Change
in Fiscal Year





On
December 5, 2006, our Board of Directors approved the change of our fiscal
year end from April 30 to October 31. Our Annual Report on Form 10-K for
the period ended October 31, 2006 was a transition report, and included
information for the six-month transitional period from May 1, 2006 to October
31, 2006.





Year
Ended October 31, 2008 Compared to Year Ended October 31, 2007





For the
fiscal year ended October 31, 2008, we generated $36,163,919 in revenues and
cost of sales of $15,980,638. With these revenues and cost of sales for the year
ended October 31, 2008, we had a net income of $11,980,528. For the fiscal year
ended October 31, 2007, we generated $28,040,174 in revenues on cost of sales of
$13,693,892. With these revenues and cost of sales for the year ended October
31, 2007, we had a net income of $9,596,632.





Revenues, Expenses and Net
Income




Year
      Ended
                          October
      31, 2008
                        
                        
                        Year
      Ended
                          October
      31, 2007Revenue
                        
                        $
                        $36,163,919
                        
                        
                        $
                        28,040,174Cost
      of Sales
                        
                        
                        (15,980,638
                        )
                        
                        
                        (13,693,892
                        )Selling
      and Distribution Expenses
                        
                        
                        (163,355
                        )
                        
                        
                        (166,567
                        )Advertising
      Expenses
                        
                        
                        (3,155,063
                        )
                        
                        
                        (1,358,900
                        )General
      and Administrative Expenses
                        
                        
                        (2,620,656
                        )
                        
                        
                        (2,553,541
                        )Research
      and Development
                        
                        
                        (2,124,511
                        )
                        
                        
                        (282,009
                        )Provision
      for Doubtful Accounts
                        
                        
                        43,154
                        
                        
                        
                        (130,634
                        )Depreciation
      and Amortization
                        
                        
                        (13,578
                        )
                        
                        
                        (293,637
                        )Other
      Income (Cost)
                        
                        
                        85,993
                        
                        
                        
                        35,638Net
      Income
                        
                        $
                        $12,235,265
                        
                        
                        $
                        9,596,632


29


Revenues





Our
revenues for the year ended October 31, 2008 were 36,163,919 compared to
revenues of $28,040,174 for the year ended October 31, 2007, representing an
increase of $8,123,745, or 29%.  This increase was primarily due to
our success in marketing expansion, with an adjustment on products. During
the year ended October 31, 2008, we increased production of our products with
higher profit margins and decreased production of our products with lower profit
margins. Our revenues for the year ended October 31, 2008 consisted primarily of
sales of the following products: Acanthopanax products (approximately 53%),
Shark Power Healthcare products (approximately 17%), and other Chinese
traditional medical products (approximately 30%)





Cost
of Sales





Our cost
of sales for the fiscal year ended October 31, 2008, which consisted primarily
of raw material, labor and production costs, were $15,980,638 as compared to
cost of sales of $13,693,892 for the fiscal year ended October 31, 2007,
representing an increase of $2,286,746, or 16.7%.  The increase in our
cost of sales was primarily due to the increase of revenue.





Selling
and Distribution Expenses





Our selling and distribution expenses
consist of expenses related to the actual sales of our products and the costs we
incur in distributing those products such as expansion costs, and salaries of
sales staff. For the fiscal year ended October 31, 2008, our selling and
distribution expenses were $163,355, as compared to $166,567 for the fiscal year
ended October 31, 2007, representing a slight decrease of $3,212, or
1.9%.





Advertising
Expenses





For the
fiscal year ended October 31, 2008, we had advertising expenses of $3,155,063 as
compared to $1,358,900 for the fiscal year ended October 31, 2007, representing
an increase of $1,796,163, or 132.2%. Our advertising expenses consisted of
expenses related to the advertising of Acanthophanax and our traditional Chinese
medicines. Our advertising expenses for the fiscal year ended October 31, 2008
were substantially higher than our advertising expenses for the fiscal year
ended October 31, 2007 primarily due to our efforts to expand our market
share.





General
and Administrative Expenses





Our
general and administrative expenses were $2,620,656 for the fiscal year ended
October 31, 2008, compared to $2,553,541 for the fiscal year ended October 31,
2007, representing a slight increase of $67,115, or 2.6%. Our general and
administrative expenses for the fiscal year ended October 31, 2008 primarily
consisted of the following: $145,391 for traveling expenses, $868,402 for
payroll, $178,358 for office expenses, $69,384 for vehicle usage expenses,
$44,183 for telephone charge,  $22,801 for employee’s welfare and
$159,695 for entertainment expenses





Research
and Development





Our research and development expenses
were $2,124,511 for the fiscal year ended October 31, 2008, compared to research
and development expenses of $282,009 for the year ended October 31, 2007,
representing a significant increase of $1,842,502, or 653.3%.  This
increase was primarily due to our development of Acanthopanax cultivation and
extraction of effective parts and the increased research and development of
other medicine.


30


Depreciation
and Amortization





We had depreciation and amortization
expenses of $339,257 for the fiscal year ended October 31, 2008, with $325,679
included in the costs of good sold, compared to $293,637 for the fiscal year
ended October 31, 2007, representing an increase of $45,620, or 15.5%. For
both periods our depreciation and amortization expenses related to machinery,
equipment and vehicles.





Net
Income from Operations





Our net
income for the fiscal year ended October 31, 2008 was $11,980,528, compared to
$9,596,632 for the fiscal year ended October 31, 2007. Our net income increased
significantly due to higher revenue and sales of higher gross margin products
for the fiscal year ended October 31, 2008.





Liquidity
and Capital Resources





Our cash,
current assets, total assets, current liabilities, and total liabilities as of
October 31, 2008 and 2007, respectively, are as follows:





October 31,
                      2008
                    
                    
                    October 31,
                      2007Cash
      and Cash Equivalents
                    
                    $
                    9,747,693
                    
                    
                    $
                    10,153,603Total
      Current Assets
                    
                    
                    35,128,995
                    
                    
                    
                    22,283,186Total
      Assets
                    
                    
                    37,749,944
                    
                    
                    
                    24,889,471Total
      Current Liabilities
                    
                    
                    1,961,087
                    
                    
                    
                    3,495,971Total
      Liabilities
                    
                    
                    1,961,087
                    
                    
                    
                    3,495,971Working
      Capital
                    
                    
                    33,167,908
                    
                    
                    
                    18,787,215





Sources and Uses of
Cash





Operations





Net cash
provided by (used in) operating activities was $(1,227,941) for the year ended
October 31, 2008, compared to $8,876,363 for the year ended October 31, 2007.
Our cash from operating activities for the year ended October 31, 2008 was
primarily ($13,120,769) in net trade receivables, ($1,513,512) in inventories,
$361,427 in other net receivables, $22,642 in third party accounts payable and
accruals, and $490,903 in other payables.





Investments





Net cash used in investing activities
was $110,760 for the year ended October 31, 2008, compared to $45,741 for the
year ended October 31, 2007. For the year ended October 31, 2008 and 2007, all
our cash used in investing activities related to the acquisition of property,
plant and equipment.





Financing





Net cash
provided by financing activities was nil for the year ended October 31, 2008 and
2007.





Debt Instruments,
Guarantees, and Related Covenants





We do not
have any long term debt and no significant short term debt, and have not entered
into any guarantee arrangements or other related covenants.


31


Critical
Accounting Policies





The
preparation of our financial statements in conformity with accounting principles
generally accepted in the United States of America requires our management to
make certain estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. As such, in accordance with the use of
accounting principles generally accepted in the United States of America, our
actual realized results may differ from management’s initial estimates as
reported.  On an on-going basis, we evaluate our estimates including
the allowance for doubtful accounts and inventories, the salability and
recoverability of our products, income taxes and contingencies and remaining
useful lives of our tangible and certain intangible assets. We base our
estimates on historical experience and on other assumptions that we believes to
be reasonable under the circumstances, the results of which form our basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions.


A
summary of our significant accounting policies are located in the notes to the
financial statements which are an integral component of this
filing.





Off-balance
Sheet Arrangements





We do not
have any off-balance sheet arrangements.





Contractual
Obligations





Payments
      due by periodObligations
                      
                      Total
                      
                      1
      Year
                      
                      2
      Years
                      
                      3Years
                      
                      4YearsLong-Term
      Debt Obligations
                      
                      
                      -0-
                      
                      -0-
                      
                      
                      -0-
                      
                      -0-
                      
                      
                      -0-Capital
      Lease Obligations
                      
                      
                      -0-
                      
                      -0-
                      
                      
                      -0-
                      
                      -0-
                      
                      
                      -0-Operating
      Lease Obligations - Total
                      
                      
                      496,645
                      
                      433,649
                      
                      
                      62,996
                      
                      -0-
                      
                      
                      -0-Operating
      Lease Obligations - Related Party
                      
                      
                      307,656
                      
                      307,656
                      
                      
                      -0-
                      
                      -0-
                      
                      
                      -0-Operating
      Lease Obligations - Third Party
                      
                      
                      188,989
                      
                      125,993
                      
                      
                      62,996
                      
                      -0-
                      
                      
                      -0-Purchase
      Obligations
                      
                      
                      -0-
                      
                      -0-
                      
                      
                      -0-
                      
                      -0-
                      
                      
                      -0-Other
      Long-Term Liabilities
                      
                      
                      -0-
                      
                      -0-
                      
                      
                      -0-
                      
                      -0-
                      
                      
                      -0-Total
      Contractual Obligations
                      
                      
                      496,645
                      
                      433,649
                      
                      
                      62,996
                      
                      -0-
                      
                      
                      -0-





As noted
above, we do lease office space from Old Renhuang, but we rent the space
pursuant to a year to year lease.





ITEM
7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK





Not
required.





ITEM
8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA


33




RENHUANG
PHARMACEUTICALS, INC AND SUBSIDIARIES




CONSOLIDATED
FINANCIAL STATEMENTS




OCTOBER
31, 2008 AND 2007




INDEX
TO FINANCIAL STATEMENTS




Report
      of Independent Registered Public Accounting Firms
                F-2Consolidated
      Balance Sheets as of October 31, 2008 and 2007
                F-3
      – F-4Consolidated
      Statements of Income and Comprehensive Income for the years ended October
      31, 2008 and 2007
                F-5Consolidated
      Statements of Changes in Stockholders’ Equity for the years ended October,
      2008 and 2007
                F-6Consolidated
      Statements of Cash Flows for the years ended October, 2008 and
      2007
                F-7
      – F-8Notes
      to Consolidated Financial Statements
                F-9
      – F-21









REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM





To the
Board of Directors and Stockholders of


Renhuang Pharmaceuticals,
Inc.





We have
audited the accompanying consolidated balance sheet of Renhuang Pharmaceuticals,
Inc. (the "Company"), as of October 31, 2008, and the related consolidated
statements of income and comprehensive income, changes in stockholders' equity,
and cash flows for the year then ended. These consolidated financial statements
are the responsibility of the Company's management. Our responsibility is to
express an opinion on these consolidated financial statements based on our
audit.





We
conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement.  The Company is not
required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audits included consideration of internal
control over financial reporting as a basis for designing audit procedures that
are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company’s internal control over financial
reporting. Accordingly, we express no such opinion.  An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements.  An audit also includes assessing the
accounting principles used and significant estimates made by management, as well
as evaluating the overall financial statement presentation.  We
believe that our audit provides a reasonable basis for our opinion.





In our
opinion, the consolidated financial statements referred to above present fairly,
in all material respects, the financial position of the Company as of
October 31, 2008, and the results of their operations and cash flows for
the year then ended, in conformity with U.S. generally accepted accounting
principles.





/s/
MSPC


Certified
Public Accountants and Advisors


A
Professional Corporation





New York,
New York


August 28,
2009






REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
 To the
Directors and Stockholders of
 Renhuang
Pharmaceuticals, Inc.
 
 We have
audited the accompanying consolidated balance sheet of Renhuang Pharmaceuticals,
Inc. as at October 31, 2007, and the related consolidated statement of income,
cash flows and changes in stockholders’ equity for the year ended October 31,
2007. These consolidated financial statements are the responsibility of the
Company’s management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audit.
  We
conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.
  In our
opinion, these consolidated financial statements referred to above present
fairly, in all material respects, the financial position of Renhuang
Pharmaceuticals, Inc. as of October 31, 2007, and the results of its operations
and its cash flows for the year ended October 31, 2007 in conformity with
generally accepted accounting principles in the United States of
America.
  “Schwartz
      Levitsky Feldman LLP”/s/
      Schwartz Levitsky Feldman llpToronto,
      Ontario, Canada
              Chartered
      AccountantsMay
      15, 2008
              Licensed
      Public Accountants
 
 1167
Caledonia Road
 Toronto,
Ontario M6A 2X1
 Tel: 416
785 5353
 Fax: 416
785 5663
  F-2




RENHUANG
PHARMACEUTICALS, INC. AND SUBSIDIARIES


CONSOLIDATED
BALANCE SHEETS


AS
OF OCTOBER 31, 2008 AND 2007





ASSETS





October 31,
                            2008
                          
                          
                          October 31,
                            2007CURRENT
      ASSETSCash
      and cash equivalents (NOTE 4)
                          
                          $
                          9,747,693
                          
                          
                          $
                          10,153,603Accounts
      receivable, net (NOTE 5)
                          
                          
                          22,588,580
                          
                          
                          
                          10,480,549Inventories
      (NOTE 7)
                          
                          
                          2,625,385
                          
                          
                          
                          969,672Prepayments
                          
                          
                          33,695
                          
                          
                          
                          9,917Other
      receivables, net (NOTE 6)
                          
                          
                          133,642
                          
                          
                          
                          669,445TOTAL
      CURRENT ASSETS
                          
                          
                          35,128,995
                          
                          
                          
                          22,283,186PROPERTY, PLANT AND EQUIPMENT,
      NET(NOTE 8)
                          
                          
                          2,620,949
                          
                          
                          
                          2,606,285TOTAL
      ASSETS
                          
                          $
                          37,749,944
                          
                          
                          $
                          24,889,471





The
accompanying notes are an integral part of the consolidated financial
statements


F-3


RENHUANG
PHARMACEUTICALS, INC. AND SUBSIDIARIES


CONSOLIDATED
BALANCE SHEETS


AS
OF OCTOBER 31, 2008 AND 2007





LIABILITIES AND
STOCKHOLDERS' EQUITY





October
      31,
                            2008
                          
                          
                          October 31,
                            2007CURRENT
      LIABILITIESAccounts
      payables (NOTE 9)
                          
                          $
                          193,934
                          
                          
                          $
                          188,600Other
      payables (NOTE 10)
                          
                          
                          1,767,153
                          
                          
                          
                          3,307,371TOTAL
      LIABILITIES
                          
                          
                          1,961,087
                          
                          
                          
                          3,495,971COMMITMENTS
      AND CONTINGENCIES (NOTE 16)STOCKHOLDERS'
      EQUITYPreferred
      stock - Authorized preferred shares 1,000,000, issued and outstanding
      number of shares: nilCommon
      Stock - Authorized common shares 100,000,000, issued and outstanding
      number of shares 35,096,680 (35,096,680 in 2007) at par value of
      0.001
                          
                          
                          35,097
                          
                          
                          
                          35,097Additional
      paid-in capital
                          
                          
                          6,595,400
                          
                          
                          
                          6,627,099Reserves
      (NOTE 11)
                          
                          
                          3,036,617
                          
                          
                          
                          1,841,734Retained
      earnings
                          
                          
                          22,765,757
                          
                          
                          
                          11,980,112Accumulated
      other comprehensive income
                          
                          
                          3,355,986
                          
                          
                          
                          909,458TOTAL
      STOCKHOLDERS' EQUITY
                          
                          
                          35,788,857
                          
                          
                          
                          21,393,500TOTAL
      LIABILITIES AND STOCKHOLDERS' EQUITY
                          
                          $
                          37,749,944
                          
                          
                          $
                          24,889,471





The
accompanying notes are an integral part of the consolidated financial
statements


F-4


RENHUANG
PHARMACEUTICALS, INC. AND SUBSIDIARIES


CONSOLIDATED
STATEMENTS OF INCOME AND COMPREHENSIVE INCOME


FOR
THE YEARS ENDED OCTOBER 31, 2008 AND 2007





Year Ended
                              October 31, 2008
                            
                            
                            Year Ended
                              October 31, 2007SALES
                            
                            $
                            36,163,919
                            
                            
                            $
                            28,040,174COST
      OF SALES
                            
                            
                            (15,980,638
                            )
                            
                            
                            (13,693,892
                            )GROSS
      PROFIT
                            
                            
                            20,183,281
                            
                            
                            
                            14,346,282SELLING
      AND DISTRIBUTION EXPENSES
                            
                            
                            (163,355
                            )
                            
                            
                            (166,567
                            )ADVERTISING
      EXPENSE
                            
                            
                            (3,155,063
                            )
                            
                            
                            (1,358,900
                            )GENERAL
      AND ADMINISTRATIVE EXPENSES
                            
                            
                            (2,620,656
                            )
                            
                            
                            (2,553,541
                            )RESEARCH
      AND DEVELOPMENT
                            
                            
                            (2,124,511
                            )
                            
                            
                            (282,009
                            )(PROVISION
      FOR DOUBTFUL ACCOUNTS)/RECOVERY
                            
                            
                            (243,282
                            )
                            
                            
                            (130,634
                            )DEPRECIATION
      AND AMORTIZATION
                            
                            
                            (13,578
                            )
                            
                            
                            (293,637
                            )INCOME
      FROM OPERATIONS
                            
                            
                            11,862,836
                            
                            
                            
                            9,560,994OTHER
      INCOME
                            
                            
                            117,692
                            
                            
                            
                            35,638INCOME
      BEFORE INCOME TAXES
                            
                            
                            11,980,528
                            
                            
                            
                            9,596,632INCOME
      TAXES (NOTE 12)
                            
                            
                            —
                            
                            
                            
                            —NET
      INCOME
                            
                            $
                            11,980,528
                            
                            
                            $
                            9,596,632OTHER
      COMPREHENSIVE INCOMEFOREIGN
      CURRENCY TRANSLATION ADJUSTMENT
                            
                            
                            2,446,528
                            
                            
                            
                            855,719COMPREHENSIVE
      INCOME
                            
                            $
                            14,427,056
                            
                            
                            $
                            10,452,351BASIC
      EARNINGS PER SHARE
                            
                            
                            0.34
                            
                            
                            
                            0.27DILUTED
      EARNING PER SHARE
                            
                            
                            0.34
                            
                            
                            
                            0.27WEIGHTED
      AVERAGE NUMBER OF COMMON SHARES OUTSTANDING –BASIC
                            
                            
                            35,096,681
                            
                            
                            
                            35,039,310WEIGHTED
      AVERAGE NUMBER OF COMMON SHARES OUTSTANDING –DILUTED
                            
                            
                            35,096,681
                            
                            
                            
                            35,039,550


The
accompanying notes are an integral part of the consolidated financial
statements


F-5


RENHUANG
PHARMACEUTICALS, INC AND SUBSIDIARIES


CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY


FOR
THE YEARS ENDED OCTOBER 31, 2008 AND 2007




AccumulatedAdditional
                        
                        
                        
                        
                        
                        
                        
                        
                        OtherCommon Stock
                        
                        
                        Paid-in
                        
                        
                        
                        
                        
                        Retained
                        
                        
                        comprehensive
                        
                        
                        TotalShares
                        
                        
                        Amount
                        
                        
                        capital
                        
                        
                        Reserves
                        
                        
                        Earnings
                        
                        
                        income
                        
                        
                        EquityBalance
      at November 1, 2006
                        
                        
                        35,000,181
                        
                        
                        $
                        35,000
                        
                        
                        $
                        6,310,822
                        
                        
                        $
                        847,133
                        
                        
                        $
                        3,378,081
                        
                        
                        $
                        53,739
                        
                        
                        $
                        10,624,775Issuance
      of common stock for service
                        
                        
                        96,500
                        
                        
                        
                        97
                        
                        
                        
                        284,578
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        284,675Net
      income for the year
                        
                        
                        
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        9,596,632
                        
                        
                        
                        —
                        
                        
                        
                        9,596,632Transfer
      to reserves
                        
                        
                        
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        994,601
                        
                        
                        
                        (994,601
                        )
                        
                        
                        —
                        
                        
                        
                        —Warrants
      issued to director for service
                        
                        
                        
                        
                        
                        
                        —
                        
                        
                        
                        31,699
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        31,699Other
      comprehensive income-
      foreign currency translation
                        
                        
                        
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        855,719
                        
                        
                        
                        855,719Balance
      at October 31, 2007
                        
                        
                        35,096,681
                        
                        
                        $
                        35,097
                        
                        
                        $
                        6,627,099
                        
                        
                        $
                        1,841,734
                        
                        
                        $
                        11,980,112
                        
                        
                        $
                        909,458
                        
                        
                        $
                        21,393,500Net
      income for the year
                        
                        
                        
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        11,980,528
                        
                        
                        
                        —
                        
                        
                        
                        11,980,528Transfer
      to reserves
                        
                        
                        
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        1,194,883
                        
                        
                        
                        (1,194,883
                        )
                        
                        
                        —
                        
                        
                        
                        —Cancellation
      of Warrants
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        (31,699
                        )
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        (31,699
                        )Other
      comprehensive income-
      foreign currency translation
                        
                        
                        
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        —
                        
                        
                        
                        2,446,528
                        
                        
                        
                        2,446,528Balance
      at October 31, 2008
                        
                        
                        35,096,681
                        
                        
                        $
                        35,097
                        
                        
                        $
                        6,595,400
                        
                        
                        $
                        3,036,617
                        
                        
                        $
                        22,765,757
                        
                        
                        $
                        3,355,986
                        
                        
                        $
                        35,788,857





The
accompanying notes are an integral part of the consolidated financial
statements


F-6


RENHUANG
PHARMACEUTICALS, INC AND SUBSIDIARIES


CONSOLIDATED
STATEMENTS OF CASH FLOWS


FOR THE YEAR ENDED OCTOBER 31, 2008
AND 2007





Year Ended
                  October 31, 2008
                
                
                Year Ended
                  October 31, 2007CASH
      FLOWS FROM OPERATING ACTIVITIES:Net
      income
                
                $
                11,980,528
                
                
                $
                9,596,632Adjustments
      to reconcile net income to net cash from operating activities
      :Depreciation
      and amortization
                
                
                339,257
                
                
                
                293,637Provision
      for bad debts/(Recovery)
                
                
                243,282
                
                
                
                130,634Fair
      value of warrants issued/(cancelled) for services
                
                
                (31,699
                )
                
                
                31,699Fair
      value of shares issued for services
                
                
                —
                
                
                
                284,675Changes
      in operating assets and liabilities:Accounts
      receivable
                
                
                (13,120,769
                )
                
                
                (2,574,916
                )Inventories
                
                
                (1,513,512
                )
                
                
                (305,926
                )Amount
      due from related parties
                
                
                271,198
                
                
                
                (430,146
                )Other
      receivables
                
                
                112,338
                
                
                
                520,523Deferred
      expenses
                
                
                -—
                
                
                
                118,647Prepayments
                
                
                (22,109
                )
                
                
                95,325Accounts
      payable and accruals
                
                
                22,642
                
                
                
                (191,388
                )Other
      Payables
                
                
                490,903
                
                
                
                1,306,967NET
      CASH - OPERATING ACTIVITIES
                
                
                (1,227,941
                )
                
                
                8,876,363CASH
      FLOWS FROM INVESTING ACTIVITIES:Acquisition
      of property, plant and equipment
                
                
                (110,760
                )
                
                
                (45,741
                )NET
      CASH - INVESTING ACTIVITIES
                
                
                (110,760
                )
                
                
                (45,741
                )CASH
      FLOWS FROM FINANCING ACTIVITIES:
                
                
                —
                
                
                
                —





The
accompanying notes are an integral part of the consolidated financial
statements


F-7


RENHUANG
PHARMACEUTICALS, INC AND SUBSIDIARIES


CONSOLIDATED
STATEMENTS OF CASH FLOWS (CONTINUED)


FOR
THE YEAR ENDED OCTOBER 31, 2008 AND 2007





Year Ended
                            October 31, 2008
                          
                          
                          Year Ended
                            October 31, 2007NET
      CHANGE IN CASH AND CASH EQUIVALENTS
                          
                          
                          (1,338,701
                          )
                          
                          
                          8,830,622EFFECT
      OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS
                          
                          
                          932,791
                          
                          
                          
                          301,714Cash
      and cash equivalents, beginning of period
                          
                          
                          10,153,603
                          
                          
                          
                          1,021,267Cash
      and cash equivalents, end of period
                          
                          $
                          9,747,693
                          
                          
                          $
                          10,153,603SUPPLEMENTAL
      DISCLOSURE OF CASH FLOW INFORMATIONInterest
      paid
                          
                          
                          —
                          
                          
                          
                          —Income
      taxes paid
                          
                          
                          —
                          
                          
                          
                          —SUPPLEMENTARY
      DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIESIssuance
      of common shares for financing services
                          
                          
                          —
                          
                          
                          
                          284,675Warrants
      granted to a director for services
                          
                          
                          —
                          
                          
                          
                          31,699





The
accompanying notes are an integral part of the consolidated financial
statements


F-8


RENHUANG
PHARMACEUTICALS, INC AND SUBSIDIARIES


NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS


OCTOBER
31, 2008 AND 2007





1.
ORGANIZATION AND PRINCIPAL ACTIVITIES


Renhuang
Pharmaceuticals, Inc., (“Renhuang”) or the (“Company”) was incorporated in the
State of Nevada on August 18, 1988 as Solutions, Incorporated. Since that time,
the Company has undergone a series of name changes as follows: Suarro
Communications, Inc., e-Net Corporation, e-Net Financial Corp., e-Net.Com
Corporation, e-Net Financial.Com Corporation, Anza Capital, Inc. and finally on
July 28, 2006 the Company changed its name to Renhuang Pharmaceuticals,
Inc.




Shares of
the Company's Common Stock are trading on the pink sheet under the symbol
RHGP.




Unless
otherwise provided in this current report, all references in this current report
to “we”, “us”, “our company”, “our”, or the “Company” refer to the consolidated
Renhuang Pharmaceuticals, Inc. entity.




The
subsidiary company Harbin Renhuang Pharmaceuticals Co., Ltd (“Renhuang China”)
is incorporated at Harbin City in the People’s Republic of China (the “PRC” or
“China”) in 1996. The subsidiary is principally engaged in production and sales
of nutraceutical and bio-pharmaceutical products including tablets, drinks and
health food. The subsidiary’s sales network covers various provinces, cities,
and counties throughout China.




The
products of the Company are made in two facilities located at Harbin City with
specialized machinery.





The
economy of PRC differs significantly from the economies of industrialized
nations in such respects as structure, level of development, gross national
product, growth rate, capital reinvestment, resource allocation,
self-sufficiency, rate of inflation and balance of payments position, among
others. Only recently has the PRC government encouraged substantial private
economic activities. The Chinese economy has experienced significant growth in
the past several years, but such growth has been uneven among various sectors of
the economy and geographic regions. Actions by the PRC government to control
inflation have significantly restrained economic expansion in the recent past.
Similar actions by the PRC government in the future could have a significant
adverse effect on economic conditions in PRC.




Many laws
and regulations dealing with economic matters in general and foreign investment
in particular have been enacted in the PRC. However, the PRC still does not have
as comprehensive a system of laws as other nations, and enforcement of existing
laws may be uncertain and sporadic.




The
Company’s operating assets and primary sources of income and cash flows are of
interests in the PRC. The PRC economy has been a centrally-planned economy,
operating on the basis of annual, five-year and ten-year plans adopted by
central governmental authorities, which set out national production and
development targets. There is no assurance that the PRC government will continue
to pursue economic reforms or that there will not be any significant change in
its economic or other policies, particularly in the event of any change in the
political leadership of, or the political, economic or social conditions in, the
PRC. There is no assurance that the Company will not be adversely affected by
any such change in governmental policies or any unfavorable change in the
political economic or social conditions, the laws or regulations, or the rate or
method of taxation in the PRC.





As many
of the economic reforms which have been or are being implemented by the PRC
government are unprecedented or experimental, they may be subject to adjustment
or refinement, which may have adverse effects on the Company. Further, through
state plans and other economic and fiscal measures, it remains possible for the
PRC government to exert significant influence on the PRC
economy.


F-9


2.
BASIS OF PRESENTATION




The
consolidated financial statements include the financial statements of the
Company and its wholly-owned subsidiaries Harbin Renhuang Pharmaceutical Company
Limited (the “BVI”) and Harbin Renhuang Pharmaceutical Co. Ltd. (“Renhuang
China”) and are prepared in accordance with generally accepted accounting
principles of the United States of America.





3.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES




A.
CASH AND CASH EQUIVALENTS




The
Company considers cash and cash equivalents to include cash on hand and demand
deposits with banks with an original maturity of three months or
less.




B.
ACCOUNTS RECEIVABLE, NET




Accounts
receivable are recognized and carried at the original invoice amount less
allowance for any uncollectible amounts. An account is considered past due
after  180 days and 90 days from the invoice date as at October
31, 2008 and 2007, respectively. The Company extended its standard credit terms
to 180 days during 2008 in order to increase its market share. The allowance on
the doubtful accounts was $442,912 as at October 31, 2008 ($134,295 in 2007).
The Company does not accept returns or offer any post-sales marketing supporting
to customers,





C.
INVENTORIES




Inventories
are stated at the lower of cost or net realizable value. Production cost is
allocated at FIFO and overhead cost is calculated on the weighted average
basis.  The cost includes all costs to acquire, transport and process
inventories to their present location and condition. The Company evaluates the
net realizable value of its inventories on a regular basis and records a
provision for loss, if necessary, to reduce inventories to their net realizable
value. There were $64,147 of
inventory reserve provisions recorded at October 31,
2008.


F-10


3.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (CONTINUED)





D.
PROPERTY, PLANT AND EQUIPMENT




Property,
plant and equipment are carried at cost. The cost of repairs and maintenance is
expensed as incurred; major replacements and improvements are
capitalized.




When
assets are retired or disposed of, the cost and accumulated depreciation are
removed from the accounts, and any resulting gains or losses are included as
components of income in the year of disposition.




The
Company records depreciation of its property, plant and equipment on a
straight-line basis over the estimated useful lives of the assets based on their
costs. The useful lives for property, plant and equipment are estimated as
follows:




Plant
      and machinery
                    10
      yearsOffice
      equipment and furnishings
                    5
      to 10 yearsMotor
      vehicles
                    5
      to 10 years




E.
FAIR VALUE OF FINANCIAL INSTRUMENTS




Effective
February 3, 2008, the Company adopted Statements of Financial Accounting
Standards (“SFAS”) No. 157, “Fair Value Measurements,” (“SFAS 157”), as it
applies to financial assets and liabilities that are recognized or disclosed at
fair value on a recurring basis. SFAS 157 defines fair value, establishes a
framework for measuring fair value in accordance with generally accepted
accounting principles and expands disclosures about fair value measurements. The
SFAS 157 fair value hierarchy consists of three levels: Level 1 fair values are
valuations based on quoted market prices in active markets for identical assets
or liabilities that the Company has the ability to access; Level 2 fair values
are those valuations based on quoted prices for similar assets or liabilities,
quoted prices in markets that are not active, or other inputs that are
observable or can be corroborated by observable data for substantially the full
term of the assets or liabilities; and Level 3 fair values are valuations based
on inputs that are supported by little or no market activity and that are
significant to the fair value of the assets or liabilities. The adoption of SFAS
157 as it applies to financial assets and liabilities that are recognized or
disclosed at fair value on a recurring basis did not have and is not expected to
have a significant impact on the Company’s consolidated financial position,
results of operations or cash flows.




The
carrying value of financial instruments including cash, accounts receivables,
other receivables, accounts payable, other payables and accrued expenses and
debts, approximates their fair value at October 31, 2008 due to the relatively
short-term nature of these instruments. As of October 31, 2008, all financial
instruments recorded by the Company are considered Level 1 as that term is
defined in SFAS 157.





F.
INCOME TAXES




The
Company accounts for income tax under the provisions of SFAS No. 109,
“Accounting for Income Taxes,” which requires recognition of deferred tax assets
and liabilities for the expected future tax consequences of events that have
been included in the consolidated financial statements. Deferred income taxes
are provided using the liability method. Under the liability method, deferred
income taxes are recognized for all significant temporary differences between
the tax and financial statement bases of assets and liabilities. In addition,
the Company is required to record all deferred tax assets, including future tax
benefits of capital losses carried forward, and to record a “valuation
allowance” for any deferred tax assets where it is more likely than not that the
asset will not be realized.


F-11


3.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (CONTINUED)





F.
INCOME TAXES (CONTINUED)





In
accordance with the relevant income tax laws applicable to wholly foreign owned
enterprises operating in PRC, the profits of the Company are fully exempt from
income tax for two years (“tax holiday”), commencing from the first profit
making year of operations, followed by a 50% exemption for the immediate next
three years (“tax preferential period”), after which the profits of the Company
will be taxable at the full rate, currently 25% (See Note 12).




G.
RELATED PARTIES




Parties
are considered to be related if one party has the ability, directly or
indirectly, to control the other party or exercise significant influence over
the other party in making financial and operational decisions. Parties are also
considered to be related if they are subject to common control or common
significant influence. Related parties may be individuals or corporate entities
(See Note 15).





H.
IMPAIRMENT OF LONG-TERM ASSETS





The
Company reviews long-lived assets for potential impairment based on a review of
projected undiscounted cash flows associated with these assets. Long-lived
assets are included in impairment evaluations when events and circumstances
exist that indicate the carrying amount of these assets may not be recoverable.
Measurement of impairment losses for long-lived assets that the Company expects
to hold and use is based on the estimated fair value of the assets. Therefore,
future changes in the Company’s strategy and other changes in its operations
could impact the projected future operating results that are inherent in
estimates of fair value, resulting in impairments in the future. Additionally,
other changes in the estimates and assumptions, including the discount rate and
expected long-term growth rate, which drive the valuation techniques employed to
estimate the fair value of long-lived assets could change and, therefore, impact
the assessments of impairment in the future.  As of October 31, 2008,
management expects its long-lived assets to be fully recoverable.





I.
FOREIGN CURRENCY TRANSLATION





The
company maintains its books and accounting records in its functional currency,
the Renminbi, (which is the PRC's currency).




Foreign
currency transactions in RMB are reflected using the temporal method. Under this
method, all monetary items are translated into the functional currency at the
rate of exchange prevailing at the balance sheet date. Non-monetary items are
translated at historical rates. Income and expenses are translated at the rate
in effect on the transaction dates. Transaction gains and losses, if any, are
included in the determination of net income for the period.




In
translating the financial statements of the Company from its functional currency
into its reporting currency in United States dollars, balance sheet accounts are
translated using the closing exchange rate in effect at the balance sheet date
and income and expense accounts are translated using an average exchange rate
prevailing during the reporting period. Adjustments resulting from the
transaction, if any, are included in accumulated other comprehensive income in
stockholders’ equity.





The RMB
is not freely convertible into foreign currencies and all foreign exchange
transactions must take place through authorized institutions. No representation
is made that the RMB amounts could have been, or can be, converted into United
States dollars at the rates used in translation. The Foreign exchange rate
between the RMB and the United States dollar on October 31, 2008 and 2007 and
the average for the years the ended are:


F-12


3.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (CONTINUED)





I.
FOREIGN CURRENCY TRANSLATION (CONTINUED)





2008
                  2007Balance
      Sheet- Year end RMB : US$ exchange rate
                  
                  6.8258:1
                  
                  7.4820:1Operating
      Statement: Average yearly RMB : US$ exchange rate
                  
                  7.0467:1
                  
                  7.6917:1




J.
USE OF ESTIMATES




The
preparation of financial statements in conformity with generally accepted
accounting principles in the United States of America requires management to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements, and the reported amounts of revenue and expenses
during the reporting period. Significant estimates primarily related to the
realizable value of accounts receivable, other receivables, inventories, the
useful lives of plant and equipment and accruals of liabilities. Actual results
when ultimately realized could differ from those estimates.




K.
REVENUE RECOGNITION




The
Company recognizes revenue when the significant risks and rewards of ownership
have transferred pursuant to PRC law, including factors such as when persuasive
evidence of an arrangement exists, delivery has occurred, the sales price is
fixed and determinable, and collectability is reasonably assured; this policy is
in accordance with the provisions of Staff Accounting Bulletin No.
104.  Renhuang generally recognizes products sales when the product is
shipped. Revenue for product sold on consignment is recognized when the sales
agent uses the product.




The
Company provides rebates to its sales agents  (which act as
wholesalers) as an incentive plan. The rebate rate is set on a
product-by-product basis. When revenue is recognized, the rebate is accounted
for as an offset to revenues in accordance with EITF Issue No. 01-9, Accounting
for Consideration Given by a Vendor to a Customer (Including a Reseller of the
Vendor’s Products). On average, the rebate rate is 16% and 17% of gross revenue
in 2008 and 2007, respectively.




L.
CERTAIN RISKS AND CONCENTRATIONS




Financial
instruments that potentially subject the Company to significant concentrations
of credit risk consist primarily of trade accounts receivable. The Company
performs ongoing credit evaluations with respect to the financial condition of
its creditors, but does not require collateral. In order to determine the value
of the Company's accounts receivable, the Company records a provision for
doubtful accounts to cover probable credit losses. Management reviews and
adjusts this allowance periodically based on historical experience and its
evaluation of the collectability of outstanding accounts
receivable.




The
Company’s financial instruments that are exposed to concentration of credit risk
consist primarily of cash and cash equivalents, accounts receivable from
customers and other receivables. Cash and cash equivalents are maintained with
major banks in the PRC.





The
Company is subject to the consideration and risks of operating in the PRC. These
include risks associated with the political and economic environment, foreign
currency exchange and the legal system in the PRC.


F-13


3.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (CONTINUED)





M.
RESEARCH AND DEVELOPMENT




Research
and development (“R&D”) costs are expensed as incurred. Engineers and
technical staff are involved in the production of our products as well as
on-going research, with no segregation of the portion of their salaries relating
to research and development from the portion of their salaries relating to
production. The total salaries are included in cost of sales.  R&D
for the year ended October 31, 2008 and 2007 are $2,124,511 and $282,009,
respectively.




N.
ADVERTISING




Advertising
costs consist primarily of promoting the Company and the Company’s products
through television and printed advertisements in trade publications. Advertising
costs are expensed as incurred. They are separately disclosed in the
consolidated statements of income and comprehensive income.




O.
STOCK-BASED COMPENSATION




The
Company measures and records the cost of employee services received in exchange
for stock-based compensation at the grant date fair value of the
award.  This method is in accordance with SFAS No. 123 (revised
2004), “Share-Based Payment”.




P.
CLASSIFICATION OF OPERATING COSTS AND EXPENSES




The
Company records its operating costs and expenses using the following general
classifications:




Cost of Goods
Sold


Cost of
goods sold consists primarily of raw materials, direct labor and manufacturing
overhead. Manufacturing overhead includes an allocation of purchasing and
receiving costs, inspection fees, warehousing utilities, supplies, factory and
equipment repairs and maintenance, safety equipment and supplies, packing
materials, depreciation and loading fees.




Selling
Expenses


Selling
expenses includes primarily of travel and entertainment, maintenance, payroll
for sales staff, payroll taxes and benefits, telephone and utilities, insurance,
sales commissions and exports fees.




General and Administrative
Expenses


General
and administrative expenses includes primarily of general office expenses,
travel and entertainment, transportation, administrative payroll, payroll taxes
and benefits, maintenance, telephone, utilities, printing, professional fees,
continuing education, licenses and fees.





R.
EARNINGS PER SHARE




The
Company reports earnings per share in accordance with SFAS No. 128, “Earnings
per Share.” Basic earnings per share are computed by dividing income available
to common shareholders by the weighted average number of common shares
available. Diluted earnings per share is computed using the treasury stock
method whereby the denominator is increased by the net dilution on the exercise
of the warrants and if the additional common shares were
dilutive.


F-14


3.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (CONTINUED)
 
 S.
COMPREHENSIVE INCOME
  The
Company has adopted the provisions of SFAS No. 130, "Reporting Comprehensive
Income" ("SFAS No. 130"). SFAS No. 130 establishes standards for the reporting
and display of comprehensive income, its components and accumulated balances in
a full set of general-purpose financial statements. SFAS No. 130 defines
comprehensive income to include all changes in equity except those resulting
from investments by owners and distributions to owners, including adjustments to
minimum pension liabilities, accumulated foreign currency translation, and
unrealized gains or losses on marketable securities. In the current period, the
only component of other comprehensive income is foreign translation gain of
$2,446,528  ($855,719
in 2007), which has been recorded as the accumulative other comprehensive income
in the balance sheet. Consequently, the comprehensive income for the period
ended October 31, 2008 and 2007 was $14,427,056 and $10,452,351,
respectively.
  T.
RECENT PRONOUNCEMENTS
  The
Company adopted SFAS 157 effective January 1, 2008, except for the nonfinancial
assets and liabilities that are subject to a one-year deferral allowed by FASB
Staff Position (FSP) SFAS 157-2 (“ FSP SFAS 157-2”). FSP SFAS 157-2 delays the
effective date of SFAS 157 until fiscal years beginning after November 15, 2008
for nonfinancial assets and liabilities that are not recognized or disclosed at
fair value in the financial statements on a recurring basis (at least annually).
The adoption of SFAS 157 did not have a material effect on our financial
statements. The Company does not expect the adoption of SFAS 157 will have a
material effect on our financial statements beginning in year 2009 as it relates
to the items subject to the one-year deferral allowed by FSP SFAS
157-2.
 
 In
February 2007, the Financial Accounting Standards Board (“FASB”) issued
Statement No. 159 “The Fair Value Option for Financial Assets and Financial
Liabilities” (SFAS 159). This statement permits companies to choose to measure
many financial assets and liabilities at fair value. Unrealized gains and losses
on items for which the fair value option has been elected are reported in
earnings. SFAS 159 is effective for fiscal years beginning after November 15,
2007. The adoption of SFAS 159, effective January 1, 2008, did not have a
material impact on the Company’s financial statements.
 
 In
December 2007, the FASB issued SFAS No. 141(R), “Business
Combinations” (“SFAS 141(R)”). SFAS 141(R) requires an acquirer to
recognize the assets acquired, the liabilities assumed, and any noncontrolling
interest in an acquiree at the acquisition date, measured at their fair values
as of that date; the immediate expense recognition of transaction costs and the
accounting for restructuring costs separately from the business combination.
This Statement also requires the acquirer in a business combination achieved in
stages (sometimes referred to as a step acquisition) to recognize the
identifiable assets and liabilities, as well as the noncontrolling interest in
the acquiree, at the full amounts of their fair values. SFAS 141(R) is
effective for the Company’s fiscal year beginning January 1, 2009 on a
prospective basis.
  F-15
  3.
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES (CONTINUED)
 
 T.
RECENT PRONOUNCEMENTS (CONTINUED)
 
 In
December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests
in Consolidated Financial Statements — an amendment of ARB No. 51”(“SFAS 160”).
SFAS 160 requires entities to report noncontrolling (minority) interests of
consolidated subsidiaries as a component of shareholders’ equity on the balance
sheet; include all earnings of a consolidated subsidiary in consolidated results
of operations; and treat all transactions between an entity and the
noncontrolling interest as equity transactions between the parties.
SFAS 160 is effective for the Company’s fiscal year beginning
January 1, 2009, and adoption is prospective only; however, the
presentation and disclosure requirements must be applied retrospectively.
The Company does not consolidate any partially owned subsidiaries and therefore
does not expect the application of this standard to have a material impact on
its consolidated financial position, cash flows or results of
operations.
 In March
2008, the FASB issued Statement No. 161, Disclosures about Derivative
Instruments and Hedging Activitiesan amendment of SFAS
133 ("SFAS 161"). This Statement will require enhanced disclosures about
derivative instruments and hedging activities to enable investors to better
understand their effects on an entity's financial position, financial
performance and cash flows. It is effective for financial statements issued for
fiscal years and interim periods beginning after November 15, 2008, with early
application encouraged. The Company does not expect the adoption of SFAS 161 to
have a material impact on its financial position, results of operations or cash
flows.
 
 In May
2008, the FASB issued SFAS No. 162, "The Hierarchy of Generally Accepted
Accounting Principles" (SFAS No.162). SFAS No. 162 identifies the sources of
accounting principles and the framework for selecting the principles used in the
preparation of financial statements. SFAS No. 162 is effective 60 days following
the SEC's approval of the Public Company Accounting Oversight Board amendments
to AU Section 411, "The Meaning of Present Fairly in Conformity with Generally
Accepted Accounting Principles". The implementation of this standard will not
have a material impact on the Company's financial position and results of
operations.
 
 4.
CASH AND CASH EQUIVALENTS
 
 Cash and
cash equivalents as of October 31, 2008 and 2007 consist of the
following:
 
 2008
                                                        
                                                        
                                                        2007Cash
      on hand
                                                        
                                                        $
                                                        20,880
                                                        
                                                        
                                                        $
                                                        28,657Cash
      in banks
                                                        
                                                        
                                                        9,726,813
                                                        
                                                        
                                                        
                                                        10,124,946$
                                                        9,747,693
                                                        
                                                        
                                                        $
                                                        10,153,603
  F-16
  5.
ACCOUNTS RECEIVABLE, NET
 
 The
Company's accounts receivable as at October 31, 2008 and 2007 are summarized as
follows:
 
 2008
                                              
                                              
                                              2007Accounts
      receivable
                                              
                                              $
                                              23,031,492
                                              
                                              
                                              $
                                              10,614,844Less:
      Allowance for doubtful accounts
                                              
                                              
                                              (442,912
                                              )
                                              
                                              
                                              (134,295
                                              )Accounts
      receivable, net
                                              
                                              $
                                              22,588,580
                                              
                                              
                                              $
                                              10,480,549
 
 As at
October 31, 2008, there are two debtors which accounted for $2,965,984 and
$2,905,478 of accounts receivable which are approximately 12% and 12% of the
total balance, respectively.
 
 The
customers from whom the sales amounts are over 10% of the total sales for the
year ended October 31, 2008 and 2007 are:
 
 2008
                                                  
                                                  2007Customer
      A:
                                                  
                                                  $
                                                  4,511,575
                                                  
                                                  10%
                                                  
                                                  $
                                                  3,743,234
                                                  
                                                  11%Customer
      B:
                                                  
                                                  $
                                                  4,464,943
                                                  
                                                  10%
                                                  
                                                  $
                                                  3,563,758
                                                  
                                                  10%
 
 6.
OTHER RECEIVABLES
 
 Other
receivables as of October 31, 2008 and 2007 consist of the
following:
 
 2008
                                
                                
                                2007Due
      from third parties
                                
                                $
                                493,525
                                
                                
                                $
                                233,268Due
      from related parties (See Note 15)
                                
                                
                                -
                                
                                
                                
                                482,365Less:
      allowance for doubtful accounts
                                
                                
                                (359,883
                                )
                                
                                
                                (46,188
                                )$
                                133,642
                                
                                
                                $
                                669,445
 
 7.
INVENTORIES
  The
Company's inventories at October 31, 2008 and 2007 are summarized as
follows:
 
 2008
                                              
                                              
                                              2007Raw
      materials
                                              
                                              $
                                              2,440,429
                                              
                                              
                                              $
                                              905,227Finished
      goods
                                              
                                              249,103
                                              
                                              
                                              
                                              64,445Less:
      Valuation allowance
                                              
                                              
                                              (64,147
                                              )
                                              
                                              
                                              —$
                                              2,625,385
                                              
                                              
                                              $
                                              969,672
  The
finished goods included $139,449 and $0 consignment goods as at October 31, 2008
and 2007, respectively.
  F-17
  
 8.
PROPERTY, PLANT AND EQUIPMENT, NET
 
 2008
                                                
                                                
                                                2007Cost:Machinery
      and equipment
                                                
                                                $
                                                3,350,762
                                                
                                                
                                                $
                                                2,959,892Office
      equipment and furnishings
                                                
                                                
                                                53,015
                                                
                                                
                                                
                                                38,649Motor
      vehicles
                                                
                                                
                                                50,388
                                                
                                                
                                                
                                                48,3643,454,165
                                                
                                                
                                                
                                                3,046,905Less:
      Accumulated depreciation
                                                
                                                
                                                (833,216
                                                )
                                                
                                                
                                                (440,620
                                                )Net
      book value
                                                
                                                $
                                                2,620,949
                                                
                                                
                                                $
                                                2,606,285
 
 For the
year ended October 31, 2008, depreciation expenses relating to property, plant
and equipment were $339,257, consisting of $325,679 recorded as Cost of Sales
and $13,578 in general and administrative expenses and $293,637 for the year
ended October 31, 2007.
 
 On March
3, 2007, the Company entered into an agreement to purchase certain assets and/or
the right to use those assets from ZhangFa ShiYe Qingyang
(“QingYang”).  The Company paid a deposit of approximately $467,000 to
QingYang and agreed to assume a bank loan of approximately $165,000 to secure
the rights.  The loan amount is included in other liabilities as of
October 31, 2008 and 2007.  The assets, which are comprised
of  property, equipment and inventory, are pledged as collateral
against the bank loan.   Although QingYang transferred
operational control of the assets to the Company it was unable to transfer
ownership.  Legal title can only pass upon the agreement of the bank
and local government authorities.  After paying the deposit, the
Company began negotiating with the bank and local authorities to settle all
outstanding issues and secure full ownership of the assets.  As of
October 31, 2007, the Company had not finalized those
negotiations.  As the Company did not have legal title to the assets,
it determined to record an impairment reserve against the entire deposit amount
at that date.  The $467,000 impairment is included in general and
administrative expenses.
 
 9.
ACCOUNTS PAYABLE
  Accounts
payable of $193,934 and $188,600 as of October 31, 2008 and 2007 consist of
balances payable to third party suppliers.  Amounts owed to three
individual suppliers each exceeded 10% of total accounts payable at October 31,
2008; there balances were $57,825, $46,283 and $39,076, respectively,
which accounted for 30%, 24% and 20% of gross accounts payable,
respectively.
  The
suppliers from whom the purchased amounts are over 10% of the total purchases
for the year ended October 31, 2008 and 2007 are:
 
 2008
                            
                            2007Supplier
      A:
                            
                            $
                            3,571,254
                            
                            25%
                            
                            $
                            2,330,232
                            
                            25%Supplier
      B:
                            
                            $
                            1,776,373
                            
                            12%
                            
                            $
                            1,189,098
                            
                            13%Supplier
      C:
                            
                            $
                            1,379,880
                            
                            10%
                            
                            $
                            992,851
                            
                            11%
 
 10.
OTHER PAYABLES
  The
balance as at October 31, 2008 mainly includes due to related party $93,738, VAT
and other taxes payable of $693,607, and social insurance payable of
$720,498.  The payable to related party is due to Old Renhuang which
has no payment term and is non-interest bearing. Old Renhuang paid the
professional fee on behalf of Renhuang during the reverse
merger.
  F-18
 
 As at
October 31, 2007, the balance includes sales professional fee payable $332,500,
sales rebates payable of $1,591,138, VAT payable of $589,410, and social
insurance payable of $343,046.
  11.
RESERVES
  The
reserve funds are comprised of the following:
  2008
                            
                            2007Statutory
      surplus reserve fund
                            
                            $
                            2,754,240
                            
                            
                            $
                            1,559,357Public
      welfare fund
                            
                            
                            282,377
                            
                            
                            
                            282,377$
                            3,036,617
                            
                            
                            $
                            1,841,734
 
 Pursuant
to the relevant laws and regulations of the PRC, the Company is required to
annually transfer 10% of its after tax profit as reported on financial
statements prepared under the accounting principles of the PRC to a statutory
surplus reserve fund until the balance reaches 50% of the registered share
capital.  This reserve can be used to make up any losses incurred or
to increase share capital.  Except for reducing losses incurred, any
other application may not result in this reserve balance falling below 25% of
the registered capital.
  Prior to
January 1, 2007, the Company was required each year to transfer 5% of its after
tax profit as reported on financial statements prepared under the accounting
principles of the PRC to the public welfare funds.  This reserve was
restricted to capital expenditure for employees’ collective welfare facilities
that are owned by the Company.  The public welfare funds are not
available for distribution to the stockholders (except in
liquidation).  Once capital expenditures for staff welfare facilities
have been made, an equivalent amount must be transferred from the public welfare
funds to the discretionary common reserve funds.  Due to a change in
PRC law, appropriation of profit to the public welfare funds is no longer
required.
 
 12.
INCOME TAXES
  The
Company is subject to state and local income taxes within the PRC at the
applicable tax rate as reported in their PRC statutory financial statements in
accordance with the relevant income tax laws.
  For the
year of 2007 and 2008, the Company was granted a tax holiday and is entitled to
full exemption from corporation income taxes through December 2008. From 2009
onwards, the Company will also be subject to a special income tax rate of 15% as
it is an eligible wholly foreign owned company.
  Had the
company not been granted the tax holiday or been an eligible wholly foreign
owned company, the income tax provision at the general PRC income rate of 25%
starting from January 1, 2008 and 33% previously would have been approximately
US$2,995,132 and US$3,167,000 for the years ended October 31, 2008 and 2007
respectively.
  13.
COMMON STOCK
  During
the year ended October 31, 2008, no common stock was issued.  During
the year ended October 31, 2007 the company issued a total of 96,500 common
stock for financing service with fee of $ 284,675.
  F-19
  14.
WARRANTS
 The Company entered into a Director
appointment agreement with Mr. Magnus Moliteus dated April 16, 2007, pursuant to
which the Company issued Mr. Magnus Moliteus 15,000 warrants, which expire on
April 16, 2010, to purchase 15,000 shares of Renhuang’s common stock at $3.02
per share. On July 31, 2007, 10,000 warrants were issued to Mr. Magnus Moliteus.
The warrants were cancelled during fiscal 2008.
 
 Transactions
involving warrants are summarized as follows:
 
 Number of
                        Shares
                      
                      Weighted
                        Average Price
                        Per ShareOutstanding
      at October 31, 2006
                      
                      
                      —
                      
                      
                      —Granted—
      April 16, 2007
                      
                      
                      15,000
                      
                      $
                      3.02—
      July 31, 2007
                      
                      
                      10,000
                      
                      $
                      2.50Exercised
                      
                      
                      —
                      
                      
                      —Cancelled
      or expired
                      
                      
                      —
                      
                      
                      —Outstanding
      at October 31, 2007
                      
                      
                      25,000
                      
                      $
                      2.81Granted
                      
                      
                      —
                      
                      
                      —Exercised
                      
                      
                      —
                      
                      
                      —Cancelled
      or expired
                      
                      
                      (25,000)
                      
                      
                      —Outstanding
      at October 31, 2008
                      
                      
                      —
                      
                      
                      —
 
 15.
RELATED PARTY TRANSACTIONS
  The
      Company rented property and plant from Harbin Renhuang Pharmaceutical
      Stock Co. Ltd., a Company owned by the Company’s major
      shareholder.  The lease term is from May 1, 2008 to May 1, 2009,
      with monthly rental payment of
$49,669.
  16.
COMMITMENTS AND CONTINGENCIES
  A.
CAPITAL AND LEASE COMMITMENTS
 
 The Company rented an office from Hei
Long Jiang Jiu San You Zhi Co., Ltd. The lease term is from May 1, 2007 to
April 30, 2010, with average monthly rental payment
$9,393.
 
 The
minimum payments for the rental leases as followings:
 
 October 31, 20082009
                                      
                                      $
                                      433,6492010
                                      
                                      
                                      62,9962011
                                      
                                      
                                      02012
                                      
                                      
                                      02013
                                      
                                      
                                      0Total
                                      
                                      $
                                      496,645
  F-20
 
 B.
LEGAL PROCEEDINGS
  The
Company is not currently involved in any litigation. There is no action, suit,
proceeding, inquiry or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending or, to the
knowledge of the executive officers of the Company.
  17. EMPLOYEE
WELFARE PLAN
  Regulations
in the PRC require the Company to contribute to a defined contribution
retirement plan for all permanent employees. Pursuant to the mandatory
requirement from the local authority in the PRC, the retirement pension
insurance, unemployment insurance, health insurance, injury insurance and
pregnancy insurance are established for the employees during the term of
employment. For the year ended October 31, 2008, the level of contribution to
these funds was determined at 22% of the average employee salary determined by
the Social Welfare Bureau. The Company accured in the amount of $212,047 as of
October 31, 2008 in other payables.
  18.
VULNERABILITY DUE TO CERTAIN CONCENTRATIONS
  The
Company faces a number of risks and challenges since its operations are in the
PRC. The Company's operations in the PRC are subject to special considerations
and significant risks not typically associated with companies in North America
and Western Europe. The Company's results may be adversely affected by changes
in the political and social conditions in the PRC, and by changes in
governmental policies with respect to laws and regulations, anti-inflationary
measures, currency conversion and remittance abroad, and rates and methods of
taxation, among other things.
 
 19.
SUBSEQUENT EVENT
 
 On May
15, 2009, there is an agreement between Renhuang and Allied Merit International
Investments, Inc. and Griffin Ventures Ltd (the “Investors”). The Investors
agreed to pay Renhuang $ 1.5 million in exchange for an aggregate of 2,142,856
shares of the Company’s Common Stock and 1,071,428 Warrants with an exercise
price of $0.875. The Company issued 2,142,856 shares on May 20, 2009 and
received the $1.5 million on August 7, 2009.
 
 Among the
Investors, Allied Merit International Investments, Inc. will receive 1,785,714
shares of the Company’s Common Stock and Warrants which can purchase 892,857
shares of Company’s Common Stock; Griffin Ventures Ltd. will receive 357,142
shares of the Company’s Common Stock and Warrants which can purchase 178,571
shares of Company’s Common Stock.
 
 F-21
 
 ITEM
9 - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
 
 There are
no reportable events as required by Item 304(b) of Regulation S-K.
 
 ITEM
9A(T) – CONTROLS AND PROCEDURES
 
 Evaluation
of Disclosure Controls and Procedures
 
 We
conducted an evaluation, with the participation of our Chief Executive Officer
and Principal Accounting Officer, of the effectiveness of the design and
operation of our disclosure controls and procedures, as defined in Rules
13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended,
or the Exchange Act, as of October 31, 2008, to ensure that information required
to be disclosed by us in the reports filed or submitted by us under the Exchange
Act is recorded, processed, summarized and reported, within the time periods
specified in the Securities Exchange Commission’s rules and forms, including to
ensure that information required to be disclosed by us in the reports filed or
submitted by us under the Exchange Act is accumulated and communicated to our
management, including our Chief Executive Officer and Principal Accounting
Officer, or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure. Based on that evaluation, our Chief
Executive Officer and Principal Accounting Officer have concluded that as of
October 31, 2008, our disclosure controls and procedures were not effective at
the reasonable assurance level due to the weaknesses described
below.
 
 Evaluation
of Internal Control over Financial Reporting
 
 As required by Exchange Act Rules
13a-15(f) and 15d-15(f), our management has carried out an evaluation, under the
supervision of our Chief Executive Officer and Principal Accounting Officer, of
the effectiveness of the design and operation of our internal control over
financial reporting as of October 31, 2008.
 
 Management is responsible for
establishing and maintaining adequate internal control over financial reporting.
The Company's internal control over financial reporting is a process that is
designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles, and includes those
policies and procedures that:
 
 Pertain to the maintenance of
      records that, in reasonable detail, accurately and fairly reflect the
      transactions and dispositions of assets of the
    Company,
 
 Provide reasonable assurance that
      transactions are recorded as necessary to permit preparation of financial
      statements in accordance with generally accepted accounting principles,
      and that receipts and expenditures are being made only in accordance with
      authorization of management and the board of directors of the Company,
      and
 
 Provide reasonable assurance
      regarding prevention (or timely detection) of unauthorized acquisition,
      use, or disposition of the Company's assets, which could have a material
      effect on Company consolidated financial
  statements.
  Because of certain inherent
limitations, internal control over financial reporting may not prevent or detect
misstatements.
  34
 
 A
material weakness is a control deficiency (within the meaning of the Public
Company Accounting Oversight Board (PCAOB) Auditing Standard No. 5), such that a
misstatement of the annual or interim financial statements may not be
prevented or detected. Management has identified the following
material  weakness that has caused management to conclude that, as of
October 31, 2008, our internal control over financial reporting was
not effective:
  We
      were unable to meet our requirements to timely file our Annual Report on
      Form 10-K for the year ended October 31, 2008. Management evaluated the
      impact of our inability to timely file periodic reports with the
      Securities and Exchange Commission on our assessment of our disclosure
      controls and procedures and has concluded that the control deficiency that
      resulted in the inability to timely make these filings represented an
      internal control weakness.
 
 Remediation
of Weaknesses
 
 Management
recognizes the importance of this weakness and is committed to remediation and
will institute a comprehensive remediation plan.  The plan will
include, but not be limited to, hiring finance management resources and
personnel with knowledge and experience in U.S. GAAP, and where necessary, the
plan will utilize the services of external consulting professionals in the area
of accounting advisory services.  Furthermore, the plan will
re-organize the internal audit function and establish communication channels
between the internal audit function and an audit committee.
 
 Management
intends to allocate resources to insure that reports are filed on a timely basis
in the future.
 
 Changes
in Internal Control over Financial Reporting
 
 There
were no changes in our internal control over financial reporting, as defined in
Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently
completed fiscal year that have materially affected, or are reasonably likely to
materially affect, our internal control over financial reporting.
 
 This
annual report does not include an attestation report of the company’s registered
public accounting firm regarding internal control over financial
reporting.  Management’s report was not subject to attestation by the
company’s registered public accounting firm pursuant to temporary rules of the
Securities and Exchange Commission that permit the company to provide only
management’s report in this annual report.
 
 ITEM
9B – OTHER INFORMATION
 
 There
have been no events that are required to be reported under this
Item.
 
 PART
III
 
 ITEM
10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
 
 Directors
and Executive Officers
  35
 
 The
following table sets forth the names and ages of our current directors and
executive officers, the principal offices and positions held by each person, and
the date such person became a director or executive officer. Our executive
officers are elected annually by the Board of Directors. The directors serve one
year terms until their successors are elected. The executive officers serve
terms of one year or until their death, resignation or removal by the Board of
Directors. Unless described below, there are no family relationships among any
of the directors and officers.
 
 Name
                
                Age
                
                Position(s)Shaoming
      Li
                
                46
                
                Chairman
      of the Board of Directors,
                  President
      and Chief Executive OfficerZuoliang
      Wang
                
                37
                
                Interim
      Chief Financial OfficerJiang
      He
                
                37
                
                Secretary
 
 Mr. Shaoming Li has served as
the Chairman of the Board of Directors since founding Harbin Renhuang
Pharmaceutical Co. Ltd in 1996. Mr. Li has more than 20 years experience from
the pharmaceutical and finance industry. From 1984 to 1996, Mr. Li served as
Vice Chairman of Shenzhen Health Pharmaceutical Co. Ltd, a company dedicated to
drug research, production, and sales. Mr. Li is a professor at Harbin Business
University and Northeastern Agriculture University. Mr. Li also served as Vice
Chairman of Heilongjiang Provincial Chinese Traditional Medicine Association and
Heilongjiang Provincial Medicine Association. Mr. Li Shaoming graduated from
Central University of Finance and Economics in Beijing, China with a bachelor
degree in finance.
 
 Mr. Zuoliang Wang was hired as
our interim Chief Financial Officer effective on January 25, 2007. Mr. Wang has
served as Chief Accounting Officer of Harbin Renhuang Pharmaceutical Co. Ltd.,
our wholly-owned subsidiary, since 2005. Mr. Wang has more than 10 years
experience in accounting and is familiar with our financial condition and the
internal preparation of our financial statements. From 2004 to 2005, Mr. Wang
served as the Chief Financial Officer of Harbin Huijiabei Food Co. Ltd. From
2001 to 2004, Mr. Wang served as the manager of the accounting department of
China Resource Breweries Limited, Harbin Office. Mr. Wang Zuoliang
graduated from Qiqihaer Mechanic Institute in 1994 with a bachelor degree in
engineering management.
 
 Mr. Jiang He was hired as our
as special assistant to the President in 2004. In this role he is in charge of
asset management, risk and crisis management, and internal audit. From 2001 to
2004, prior to joining our company, he was the vice general manager of
Heilongjiang Tiansheng High Tech Co. Ltd. In this position Mr. Jiang was
primarily responsible for managing projects, such as, but not limited to, Clean
Coal Projects. Mr. Jiang is currently studying for his MBA from Harbin Business
School, and is projected to get his MBA degree in 2007. He received his Masters
degree in Industrial Economics in July, 2004, and his Bachelor degree in
Management from Jilin University in 1992.
 
 To our
knowledge, none of the directors presently serve as directors of public
corporations other than Renhuang Pharmaceuticals, Inc.
 
 Board
Meetings and Committees
 
 During
the fiscal year ended October 31, 2008, we did not hold any formal meeting of
the Board of Directors, for with the exception of Mr. Shaoming Li, the other
members of the Board all resigned during 2008.
  36


On April
1, 2006, Mr. Shaoming Li and Mr. Zuoliang Wang of our Board of Directors formed
an Audit Committee. Mr. Wang is no longer on the Board of Directors or Audit
Committee. Mr. Andy Wu was appointed to our Board of Directors and as the
Chairman of the Audit Committee effective January 25, 2007. Mr. Any Wu resigned
in December of 2008. Mr. Shaoming Li is now the sole director and member of
Audit Committee. In accordance with a written charter adopted by the Company’s
Board of Directors, the Audit Committee assists the Board of Directors in
fulfilling its responsibility for oversight of the quality and integrity of the
Company’s financial reporting process, including the system of internal
controls.
 
 Code
of Ethics
 
 We have
not adopted a written code of ethics.
 
 Compensation
Committee
 
 On April
1, 2006, Mr. Shaoming Li and Mr. Zuoliang Wang of our Board of Directors formed
a Compensation Committee.
 
 ITEM
11 - EXECUTIVE COMPENSATION
 
 Executive
Officers and Directors
 
 We do not
have written employment agreements with officers or directors. Our Chairman,
President and CEO, Mr. Shaoming Li receives US $31,250 in annual salary and is
reimbursed for out of pocket expenses. Our interim Chief Financial Officer, Mr.
Wang Zuoliang, and our Secretary, Mr. Jiang He, each receive US $4,500 in annual
salary and are reimbursed for out of pocket expenses.
 
 The
Summary Compensation Table shows certain compensation information for services
rendered in all capacities for the fiscal years ended October 31, 2008 and 2007.
Other than as set forth herein, no executive officer’s salary and bonus exceeded
$100,000 in any of the applicable years. The following information includes the
dollar value of base salaries, bonus awards, the number of stock options granted
and certain other compensation, if any, whether paid or deferred.
  Name
                                      and
                                      Principal
                                      Position
                                    Year
                                    
                                    Salary
                                      ($)
                                    
                                    Bonus
                                      ($)
                                    
                                    Stock
                                      Awards
                                      ($)
                                    
                                    Option
                                      Awards
                                      ($)
                                    
                                    Nonequity
                                      incentive
      plan
                                      compensation
                                      ($)
                                    
                                    Nonqualified
      deferred compensation earnings
                                      ($)
                                    
                                    All
      other
                                      compensation
                                      ($)
                                    
                                    Total
                                      ($)Shaoming
      Li
                                    2008
                                    
                                    
                                    31,250
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    31,250President,
                                    2007
                                    
                                    
                                    31,250
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    31,250Chief
      Executive Officer, and Director
                                    2006
                                    
                                    
                                    
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    -0-
                                    
                                    
                                    -0-Zouliang
      Wang
                                    2008
                                    
                                    
                                    4,500
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    4,500Interim
                                    2007
                                    
                                    
                                    4,500
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    4,500Chief
      Financial OfficerJiang
      He
                                    2008
                                    
                                    
                                    4,500
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    -0-
                                    
                                    
                                    -0-
                                    
                                    4,500Secretary
                                    2007
                                    
                                    
                                    4,500
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    
                                    4,500
  37
  Outstanding Equity Awards at
Fiscal Year-End
 
 The
following table sets forth certain information concerning outstanding stock
awards held by the Named Executive Officers as of October 31, 2008:
  Option
      Awards
                          
                          Stock
      AwardsName
                          
                          Number
      of
                            Securities
                            Underlying
                            Unexercised
                            Options
                            (#)
                            Exercisable
                          
                          Number
      of Securities Underlying Unexercised Options
                            (#)
                            Unexercisable
                          
                          Equity
                            Incentive
                            Plan
                            Awards:
                            Number
      of
                            Securities
                            Underlying
                            Unexercised
                            Unearned
                            Options
                            (#)
                          
                          Option
      Exercise Price
                            ($)
                          
                          Option
      Expiration Date
                          
                          Number
      of Shares or Units of Stock That Have Not
Vested
                            (#)
                          
                          Market
                            Value
                            of
                            Shares
                            or
      Units
                            of
      Stock That
                            Have
                            Not
                            Vested
                            ($)
                          
                          Equity
      Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights
      That Have Not Vested
                            (#)
                          
                          Equity
                            Incentive
                            Plan
                            Awards:
                            Market
                            or
      Payout
                            Value
      of
                            Unearned
                            Shares,
                            Units
      or
                            Other
                            Rights
                            That
                            Have
      Not
                            Vested
                            ($)Shaoming
      Li
                          
                          
                          -0-
                          
                          -0-
                          
                          
                          -0-
                          
                          N/A
                          
                          N/A
                          
                          -0-
                          
                          
                          -0-
                          
                          -0-
                          
                          
                          -0-Zouliang
      Wang
                          
                          
                          -0-
                          
                          -0-
                          
                          
                          -0-
                          
                          N/A
                          
                          N/A
                          
                          -0-
                          
                          
                          -0-
                          
                          -0-
                          
                          
                          -0-Jiang
      He
                          
                          
                          -0-
                          
                          -0-
                          
                          
                          -0-
                          
                          N/A
                          
                          N/A
                          
                          -0-
                          
                          
                          -0-
                          
                          -0-
                          
                          
                          -0-Magnus
      Moliteus
                          
                          
                          25,000
                          
                          -0-
                          
                          
                          -0-
                          
                          (1
                          )
                          (1
                          )
                          -0-
                          
                          
                          -0-
                          
                          -0-
                          
                          
                          -0-
 
 (1) We entered into a Director Appointment
agreement with Mr. Magnus Moliteus who resigned in May 2008, dated April 16,
2007, pursuant to which we issued Mr. Magnus Moliteus 15,000 warrants, which
terminates on April 16, 2010, to purchase 15,000 shares of our common stock at
$3.02 per share. Pursuant to this same agreement, on July 31, 2007, 10,000
warrants were issued to Mr. Magnus Moliteus at the exercise price of $2.50 per
share. We valued the warrants using the Black-Scholes calculation model, and the
warrants were deemed to have a value of $22,442 and $9,257 respectively. See
Note 14 to the attached financial statements.
  2003
Omnibus Securities Plan
 
 On
February 28, 2003, our Board of Directors approved the Renhuang Pharmaceuticals,
Inc. 2003 Omnibus Securities Plan, which was approved by our shareholders on
April 11, 2003. The Plan offers selected employees, directors, and consultants
an opportunity to acquire our common stock, and serves to encourage such persons
to remain employed by us and to attract new employees. The plan allowed for the
award of stock and options, up to 25,000 shares (after giving effect to the
1-for-20 reverse stock split effective April 21, 2003, and the 1-for-30 reverse
stock split in 2006) of our common stock. On May 1 of each year, the number
of shares in the 2003 Securities Plan should automatically be adjusted to an
amount equal to ten percent (10%) of our outstanding stock on April 30 of the
immediately preceding year. As of October 31, 2008, there are no options or
other financial instruments outstanding under the 2003 Omnibus Securities
Plan.
  38
  Board
Compensation
 
 There are
currently no agreement with Mr. Shaoming Li, the sole director, or director
nominees for compensation. Mr. Li is entitled to reimbursement for his travel
expenses. We do not pay additional amounts for committee participation or
special assignments of the Board of Directors.
  The
following table sets forth director compensation as of October 31,
2008:
  Name
                  
                  Fees
                    Earned
                    or Paid
                    in
                    Cash
                    ($)
                  
                  Stock
                    Awards
                    ($) *
                  
                  Option
                    Awards
                    ($) *
                  
                  Non-Equity
                    Incentive Plan
                    Compensation
                    ($)
                  
                  Nonqualified
                    Deferred
                    Compensation
                    Earnings
                    ($)
                  
                  All Other
                    Compensation
                    ($)
                  
                  Total
                    ($)Shaoming
      Li
                  
                  
                  -0-
                  
                  -0-
                  
                  
                  -0-
                  
                  -0-
                  
                  
                  -0-
                  
                  -0-
                  
                  
                  -0-Fanrong
      Meng
                  
                  
                  -0-
                  
                  -0-
                  
                  
                  -0-
                  
                  -0-
                  
                  
                  -0-
                  
                  -0-
                  
                  
                  -0-Andy
      Wu
                  
                  
                  -0-
                  
                  -0-
                  
                  
                  -0-
                  (1)
                  -0-
                  
                  
                  -0-
                  
                  -0-
                  
                  
                  -0-Magnus
      Moliteus
                  
                  
                  -0-
                  
                  -0-
                  
                  
                  31,699
                  (2)
                  -0-
                  
                  
                  -0-
                  
                  -0-
                  
                  
                  31,699
  *
              Based
      upon the aggregate grant date fair value calculated in accordance with the
      Financial Accounting Standards Board (“FASB”) Statement of Financial
      Accounting Standard (“FAS”) No. 123R, Share Based
  Payment.
 
 (1) We entered into a Director appointment
agreement with Mr. Andy Wu dated February 15, 2007, pursuant to which we are
obligated to issue Mr. Wu warrants, exercisable for three (3) years, to purchase
5,000 shares of our common stock at $3.02 per share; and warrants each July 31,
beginning in 2007, exercisable for three (3) years, to purchase 5,000 shares of
our common stock at the then fair market value of our common stock. All warrants
are to be issued pursuant to the terms of form warrant agreement, with the
remaining terms to be agreed to by the parties. As of October 31, 2008, we had
not agreed to a warrant agreement or issued the warrants to Mr. Wu, and,
therefore, we did not include them as compensation in the above director’s
compensation table. Mr. Wu resigned from the Board of Directors on December 22,
2008.
 
 (2) We entered into a Director appointment
agreement with Mr. Magnus Moliteus dated April 16, 2007, pursuant to which we
issued Mr. Magnus Moliteus 15,000 warrants, which terminates on April 16, 2010,
to purchase 15,000 shares of our common stock at $3.02 per share. Pursuant to
this same agreement, on July 31, 2007, 10,000 warrants were issued to Mr. Magnus
Moliteus. We valued the warrants using the Black-Scholes calculation model, and
the warrants were deemed to have a value of $22,442 and $9,257 respectively. See
Note 16 to the attached financial statements.
  39
 
 ITEM
12 - SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
 
 The
following table sets forth, as of June 10, 2009, certain information with
respect to the Company’s equity securities owned of record or beneficially by
(i) each Officer and Director of the Company; (ii) each person who owns
beneficially more than 5% of each class of the Company’s outstanding equity
securities; and (iii) all Directors and Executive Officers as a
group.
 
 Common StockTitle of Class
                                                                        Name and Address
                                                                          of Beneficial Owner
                                                                        
                                                                        Amount and
                                                                          Nature of
                                                                          Beneficial Ownership
                                                                        
                                                                        
                                                                        Percent
                                                                          of Class (1)Common Stock
                                                                        Shaoming
      Li (2)(3)
                                                                        
                                                                        
                                                                        17,850,000
                                                                        (4)
                                                                        
                                                                        
                                                                        47.93
                                                                        %(4)Common
      Stock
                                                                        Jiang
      He (2)
                                                                        
                                                                        
                                                                        0
                                                                        
                                                                        
                                                                        
                                                                        0
                                                                        %Common
      Stock
                                                                        Zuoliang
      Wang (2)
                                                                        
                                                                        
                                                                        0
                                                                        
                                                                        
                                                                        
                                                                        0
                                                                        %Common
      Stock
                                                                        Dianjun
      Pi - Total Prosperity Company Ltd.(5)
                                                                        
                                                                        
                                                                        3,159,450
                                                                        
                                                                        
                                                                        
                                                                        8.48
                                                                        %Common
      Stock
                                                                        Tuya
      Wulan - New BVI Co.(6)
                                                                        
                                                                        
                                                                        2,975,000
                                                                        
                                                                        
                                                                        
                                                                        7.99
                                                                        %Common
      Stock
                                                                        Yun Man Cheung.-China
      Wealth Source Co.(7)
                                                                        
                                                                        
                                                                        4,278,000
                                                                        
                                                                        
                                                                        
                                                                        11.49
                                                                        %Common
      Stock
                                                                        All Directors and Officers
                                                                          As
      a Group (3 persons)
                                                                        
                                                                        
                                                                        17,850,000
                                                                        (4)
                                                                        
                                                                        
                                                                        47.93
                                                                        %(4)
 
 (1)
              Unless otherwise indicated, based
      on 37,239,537 shares of common stock issued and outstanding. Shares of
      common stock subject to options or warrants currently exercisable, or
      exercisable within 60 days, are deemed outstanding for purposes of
      computing the percentage of the person holding such options or warrants,
      but are not deemed outstanding for the purposes of computing the
      percentage of any other
person.
 
 (2)
              Indicates one of our officers or
      directors.
 
 (3)
              Unless indicated otherwise, the
      address of the shareholder is No. 281, Taiping Road, Taiping District,
      Harbin, Heilongjiang Province, 150050, P.R.
  China.
 
 (4)
              Includes 17,850,000 shares of
      Common Stock owned by Celebrate Fortune Company Limited, an entity
      controlled by Mr. Shaoming
Li.
 
 (5)
              Includes 3,159,450 shares of
      Common Stock owned by Total Prosperity Ltd., an entity controlled by Mr.
      Dianjun Pi.
 
 (6)
              Includes 2,975,000 shares of
      Common Stock owned by New BVI Co., an entity controlled by Mr. Tuya
      Wulan.
 
 (7)
              Includes 4,278,000 shares of
      Common Stock owned by China Wealth Source Company Ltd., an entity
      controlled by Mr. Yun Man
Cheung.
  40





ITEM
13 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE





The
Company had the following significant related party transactions during the year
2008:




n
            The
      Company rented property and plant from its affiliate Harbin Renhuang
      Pharmaceutical Stock Co. Ltd. The lease term is from May 1, 2008 to May 1,
      2009, with monthly rental payment of $49,669 and accordingly, the total
      rent for fiscal year ended October 31, 2008 is $298,014. Mr. Shaoming Li
      is a majority shareholder of Harbin Renhuang Pharmaceutical Stock Co.
      Ltd.





ITEM
14 – PRINCIPAL ACCOUNTING FEES AND SERVICES





Audit
Fees





During
the year ended October 31, 2008 and 2007, MSPC Certified Public Accountants and
Advisors, a Professional Corporation (“MSPC”) and Schwartz Levitsky Feldman
LLP billed us $ 200,000 and $178,000, respectively, in fees for professional
services for the audit of our financial statements and review of financial
statements included in our Forms 10-K and 10-Q’s, as applicable.





Audit
- Related Fees





During
the year ended October 31, 2008 and 2007, there were no amounts billed related
to any assurance and related services related to the performance of the audit or
review of our financial statements by either MSPC or Schwartz Levitsky Feldman
LLP.





Tax
Fees





During
the year ended October 31, 2008 and 2007, there were no amounts billed us by
either MSPC or  Schwartz Levitsky Feldman LLP for professional
services for tax preparation.





All
Other Fees





During
the year ended October 31, 2008 and 2007, MSPC and Schwartz Levitsky Feldman LLP
did not bill us for any other fees.





Of the
fees described above for the year ended October 31, 2008 and 2007, 100% were
approved by either the entire Board of Directors or the Audit Committee. The
Audit Committee’s pre-approval policies and procedures were detailed as to the
particular service and the audit committee was informed of each service and such
policies and procedures did not include the delegation of the audit committee’s
responsibilities.





41





PART
IV





ITEM
15 - EXHIBITS





Exhibit
Index





3.1
      (1)
            
            Restated
      Articles of Incorporation, as filed with the Nevada Secretary of State on
      April 21, 2003.3.2
      (5)
            
            Amendment
      to Articles of Incorporation, as filed with the Nevada Secretary of State
      on July 28, 2006.3.3
      (1)
            
            Second
      Restated Bylaws10.1
      (2)
            
            Common
      Stock Purchase Agreement dated September 19, 2005.10.2
      (2)
            
            Securities
      Purchase Agreement dated September 16, 2005.10.3
      (3)
            
            Reorganization,
      Stock and Asset Purchase Agreement dated September 30,
    2005.10.4
      (3)
            
            Stock
      Purchase Agreement dated September 30,
2005.





10.5
      (4)
            
            Securities
      Purchase Agreement dated September 16, 2005.10.6
      (6)
            
            Loan
      Agreement with Heilongjiang Yuejintiande Building and Installation Project
      Co., Ltd.10.7
      (7)
            
            Director
      Appointment Letter Agreement with Mr. Andy Wu dated February 15,
      200710.8
      (7)
            
            Director
      Appointment Letter Agreement with Mr. Magnus Moliteus dated April 16,
      200721.1
      (6)
            
            Subsidiaries
      of the Registrant23.1
            
            Consent
      of Schwartz Levitsky Feldman Llp dated September 8, 200931.1
            
            Rule
      13a-14(a)/15d-14(a) Certification of Chief Executive
    Officer31.2
            
            Rule
      13a-14(a)/15d-14(a) Certification of Chief Financial
    Officer32.1
            
            Chief
      Executive Officer Certification Pursuant to 18 USC, Section 1350, as
      Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
      2002.32.2
            
            Chief
      Financial Officer Certification Pursuant to 18 USC, Section 1350, as
      Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
      2002.





(1)
                Incorporated
      by reference to our Current Report on Form 8-K dated April 21, 2003, filed
      with the Commission on April 22, 2003.(2)
                Incorporated
      by reference from our Current Report on Form 8-K filed with the Commission
      on September 23, 2005.(3)
                Incorporated
      by reference from our Current Report on Form 8-K filed with the Commission
      on October 3, 2005.(4)
                Incorporated
      by reference from our Current Report on Form 8-K filed with the Commission
      on October 14, 2005.(5)
                Incorporated
      by reference from our Annual Report on Form 10-K filed with the Commission
      February 13, 2007.





42




(6)
                      Incorporated
      by reference from our First Amended Transition Report on Form 10-K/A filed
      with the Commission on February 22, 2007.(7)
                      Incorporated
      by reference from our Annual Report on Form 10-K filed with the Commission
      on May 29,
2008.





SIGNATURES





In
accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.





Renhuang
      Pharmaceuticals, Inc.Dated:
      September 9, 2009
                            
                            /s/
      Shaoming LiBy:
                            Shaoming
      LiChairman,
      President andChief
      Executive OfficerDated:
      September 9, 2009
                            
                            /s/
      Zuoliang WangBy:
                            Zuoliang
      WangInterim
      Chief Financial
Officer




In
accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the
dates indicated.





Dated: September
      9, 2009
                    
                    /s/
      Shaoming LiBy:
                    Shaoming
      Li,
Director




43